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Abstract 
Glioblastoma (GBM) is the most aggressive primary brain tumour in adults 
with a median overall survival of only 15 months. Despite multiple attempts, single 
agent therapies have failed in clinical trials and new strategies for combination 
treatments are urgently needed. 
Here, our aim was to predict rational combination therapies with BET inhibi-
tors (BETi) that target bromodomain and extra-terminal tail (BET) proteins. BET pro-
teins are readers of lysine acetylation on histone tails, therefore promoting gene 
transcription. BETi are currently being evaluated as anti-cancer drugs. 
First, we have assessed the biological activity of the tool drug JQ1, a small 
molecule inhibitor of BET, using glioblastoma derived sphere lines (GS-lines). The 
results suggested intermediate sensitivity of GS-lines to JQ1. Importantly, we ob-
served that JQ1 impaired the self-renewal capacity of all 4 tested GS-lines.  
With the view to identify BETi-induced vulnerabilities in cancer relevant path-
ways that may be targeted with a second drug, we obtained differential expression 
profiles of glioma sphere lines treated with the BETi JQ1. Gene set enrichment anal-
ysis using MSigDB collections revealed several significantly disturbed pathways. 
They included IFN-α response genes and signatures of response to histone deacety-
lase inhibitors (HDACi).  
In order to validate the observed down regulation of the interferon response 
genes, we primed our GS-lines with IFN-α and confirmed that interferon-stimulated 
genes (ISGs), such as MX1, OAS1, and CD274 are down regulated after a 4-hour 
exposure to JQ1. Importantly, the levels of pSTAT1 in the nucleus remained un-
changed upon JQ1 treatment, suggesting that JQ1 was acting directly on the tran-
scriptional level of ISGs and not on the IFN-induced JAK-STAT signalling. Similar 
results were obtained in adherent GBM cell lines that constitutively express ISGs. 
Moreover, in U87MG orthotopic xenografts in mice, a single i.p. injection of JQ1 
down regulated OAS1 and CD274 expression.  
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Finally, we showed that HDACi and JQ1 synergize to reduce cell viability of 
GS-lines in vitro. Further experiments are necessary to test HDACi and BETi drug 
combinations in mouse orthotopic xenografts of GS-lines.  
		
Résumé 
Le glioblastome (GBM) est la tumeur cérébrale la plus agressive avec une 
survie globale médiane de seulement 15 mois. Malgré de multiples tentatives, les 
traitements en monothérapie ont échoué dans les essais cliniques et de nouvelles 
stratégies pour les traitements combinés sont nécessaires. 
Notre objectif était de prédire les combinaisons thérapeutiques rationnelles 
avec les inhibiteurs BET (BETi) qui ciblent la bromodomaine et les protéines de la 
queue extra-terminale (BET), et qui sont actuellement évaluées comme 
médicaments anticancéreux. Premièrement, nous avons évalué l'activité biologique 
du médicament JQ1, une petite molécule inhibant BET, en utilisant des lignées de 
sphères dérivées du glioblastome (lignées-GS). Nos résultats suggèrent une 
sensibilité intermédiaire des lignées-GS à JQ1. Fait important, nous avons observé 
que JQ1 a réduit la capacité d’auto-renouvellement des quatre lignées-GS testées. 
 Afin d'identifier les vulnérabilités induites par JQ1 dans les voies 
pathologiques cancéreuses susceptibles d'être ciblées par un second médicament, 
nous avons obtenu des profils d'expression différentielle des lignées-GS traitées 
avec JQ1. L'analyse de l'enrichissement des ensembles de gènes a révélé plusieurs 
voies significativement perturbées qui comprenaient des gènes de réponse à IFN-α 
et des signatures de réponse aux inhibiteurs de l'histone désacétylase (HDACi). 
Afin de valider la régulation négative observée de la signature du gène de 
réponse à l'interféron, nous avons exposés les lignées-GS à IFN-α et confirmé que 
l’expression des gènes stimulés par interféron (ISGs), tels que MX1, OAS1 et 
CD274, est réduite par JQ1. Notamment, les niveaux de pSTAT1 dans le noyau sont 
inchangés lors du traitement JQ1, suggérant que JQ1 agissait directement au niveau 
transcriptionnel des ISG et non sur la voie JAK-STAT. Des résultats similaires ont 
été obtenus dans des lignées cellulaires GBM adhérentes qui expriment 
constitutivement des ISG. De plus, dans les xénogreffes orthotopiques U87MG chez 
la souris, une seule injection i.p. de JQ1 a diminué l'expression OAS1 et CD274. 
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Enfin, nous avons montré que HDACi et JQ1 synergisent pour réduire la 
viabilité cellulaire des lignées-GS in vitro. D'autres expériences sont nécessaires 
pour tester les combinaisons de médicaments HDACi et BETi dans des xénogreffes 
orthotopiques murines des lignées-GS. 
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 Introduction Chapter 1
1.1 Classification of glioma in adults. 
Glioma is the most common primary brain tumour in adults accounting for 
more than 70% of brain tumours. For almost 100 years glioma classification was 
based on the histological examination, it was updated in 2016 by WHO (Louis et al., 
2016a) (Fig. 1:1). Gliomas remain to be graded histologically from I to IV according 
to their malignancy. This way, grade I lesions have a low proliferative index and can 
be treated with surgical resection only. Whereas grade IV designation is applied to 
malignant, proliferating, often necrotic lesions that progress under the standard of 
care and lead to death. Patients with WHO grade II tumours typically survive over 5 
years, with grade III tumours survive 2-3 years, whereas the majority of patients di-
agnosed with grade IV tumour (glioblastoma, GBM) die within one year. 
Gliomas are stratified by the presence of IDH mutation (a point mutation in the 
Isocitrate dehydrogenase 1 or 2 gene). This way, grade IV glioma can be either IDH-
wild type (90% of the cases) or IDH-mutant. The latter associates with better surviv-
al. For the low grade gliomas (grade II-III) IDH wild-type tumours are either diffuse 
astrocytoma or a rare case of oligodendroglioma. IDH mutant low grade gliomas are 
further classified based on the chromosome arms 1p/19q codeleted (oligodendrogli-
oma) and non-codeleted (astrocytoma), the later exhibits mutations in ATRX and 
TP53 genes (Louis et al., 2016b). In summary, IDH-mutant and IDH wild-type glio-
mas are thought to arise from different cells of origin and therefore represent differ-
ent diseases.	
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Figure 1:1. Visualization of the 2016 WHO classification of gliomas. 
Multidimensional scaling demonstrates 3 major clusters of gliomas. The current 
WHO classification represents well these clusters and can be divided into:  
1) astrocytic gliomas/glioblastomas, IDH-wildtype (WHO grades II–IV);  
2) astrocytic gliomas/glioblastomas, IDH-mutant (WHO grades II–IV);  
3) oligodendroglial tumours, IDH-mutant and 1p/19q-codeleted (WHO grades II–III). 
Adapted from (Cimino et al., 2017). 
1.2 Molecular subclassification of glioblastoma 
Glioblastoma was also classified into 4 molecular subtypes comprising pro-
neural, neural, classical, and mesenchymal, which are based on gene expression. 
These subtypes were characterized by abnormalities in EGFR (classical), PDG-
FRA/IDH1 (proneural), and NF1 (mesenchymal) (Fig.1:2). Verhaak and others pro-
posed that the subtypes associate with different survival and may require different 
treatments. They showed that proneural GBM patients did not have survival ad-
vantage from RT/TMZ (combination of radiotherapy and Temozolomide) therapy, 
whereas mesenchymal and classical benefited from the standard of care (Verhaak et 
al., 2010). However, with the development of single cell RNA sequencing, it was 
demonstrated that different glioblastoma cells within the same tumour might belong 
to different molecular subtypes (Lee et al., 2017; Patel et al., 2014). Moreover, re-
cent study showed that 63% of GBMs were classified to a different expression sub-
type at recurrence. Interestingly, in the same study the loss of EGFRvIII at recur-
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rence was associated with a switch from classical to other expression subtypes 
(Wang et al., 2016). Moreover, the subtypes were recently updated to three (mesen-
chymal, proneural, and classical) after deconvolution of IDHwt GBM expression pro-
files into GBM cells and associated stroma in silico (Wang et al., 2017). All in all, 
even though the molecular subtypes are well accepted in the field, their prognostic 
value is rather limited. 
	
Figure 1:2. Four GBM expression subtypes proposed by (Verhaak et al., 2010). 
Based on gene expression GBM can be divided into 4 groups, molecular subtypes 
that are associated with mutations in the PDGFRA, EGFR, NF1, IDH1 and other 
genes. Adapted from 
https://verhaaklab.github.io/images/publpics/gbmsubtypes_header.png 
1.3 Treatment of glioblastoma patients 
The first step in glioblastoma management is surgical resection. The glioblas-
toma margins are not clear due to its invasiveness and a complete resection is often 
not achievable. However, the tumour resection allows for the pathological diagnosis. 
Radiotherapy remains a staple in glioblastoma management. From 2005, alkylating 
agent temozolomide is used in addition to radiation. The glioblastoma progression is 
often monitored by magnetic resonance imaging (MRI). The addition of te-
mozolomide concomitant and adjuvant to RT improved median overall survival from 
12.1 to 14.6 months (Stupp et al., 2009). Temozolomide mainly benefits patients with 
a methylated O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter 
(Hegi et al., 2005), and unmethylated patients should be directed to clinical trials to 
test novel agents (Hegi and Stupp, 2015). In the United States Bevacizumab (anti-
Introduction	
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VEGF (Vascular endothelial growth factor) monoclonal antibody) is approved for re-
current GBM, however clinical trials demonstrated that Bevacizumab does not signif-
icantly improve survival of patients with recurrent GBM. Whereas, in Europe Bevaci-
zumab is used off-label mainly to reduce edema of the brain (Hottinger et al., 2014).  
After the failure of more than a dozen of clinical trials adding targeted drugs to 
the standard of care (Prados et al., 2015), Tumour Treating Fields (TTFields, trade-
mark Optune, Novocure) were reported to give 2 months overall survival benefit for 
GBM patients (Fig. 1:3). TTFields are low-intensity alternating electric fields that 
were shown to block mitosis. They are delivered continuously to the brain by a medi-
cal device that is worn on the scalp at least 18 hours per day. The treatment with 
TTFields takes place after TMZ/RT combination and lasts for at least 4 weeks, but 
maximum 7 weeks after last day of radiotherapy, together with TMZ for maintenance. 
There is no biomarker that predicts the response to TTFields so far, and MGMT 
methylation status did not play a significant role in response to TTFields (Stupp et 
al., 2017). All in all, the standard of care is evolving, TTFields plus TMZ should be-
come the new standard at least for those patients who are willing to undergo this 
therapy. 
	
Figure 1:3. Kaplan-Meier curves for progression-free survival and overall sur-
vival for GBM patients treated with TMZ versus TTField + TMZ.  
(A) Median progression-free survival from randomization for TMZ treated group was 
4 months and for the TTFields + TMZ group was 6.7 months. 
(B) Median overall survival from randomization was 16 months for TMZ alone group 
and 20.9 months for the TTFields + TMZ group. Adapted from (Stupp et al., 2017). 434 of 695 patients (62%). The local diagnosis of glioblas-tomawas confirmed in 419 of 434 patients (97%). For 6 cases
WHOgrade II or III diagnosesweremade, and for the remain-
ing9patients, the available tissue for reviewdid not allow for
a definitive diagnosis or showed no tumor, yet all these pa-
tientswere included in the intent-to-treat analysis. Tumor tis-
sue for MGMT testing was available for 82% of the patients;
of thecaseswithavalid test (518of571)41%wereMGMTmeth-
ylated (40% TTFields plus temozolomide group and 45% for
the temozolomide-only group). In 7% of tumors, expression
of the IDH1-R132H mutant was demonstrated by a positive
immunohistochemistry, EGFRwas amplified in 40%.
Tumor location (lobe, hemisphere) in the brain was also
comparable between the groups. The median time from his-
tological diagnosis to randomization was 3.8months (range,
1.7-6.2 months) for patients in the TTFields plus temozolo-
mide group, and 3.7months (range, 1.4-6.3months) for those
in the temozolomide-only group. Median time from the end
of radiotherapy to randomizationwas 37days in the TTFields
plus temozolomide group and 36 days in the temozolomide-
only group and occurred inmost patients after starting of the
first cycle of maintenance temozolomide. Median time from
randomization to TTFields was 5 days (IQR, 3-7 days).
Treatment Delivery
Allpatientshadcompletedradiotherapyandconcomitanttemo-
zolomideasper local practice. Themediannumberof temozo-
lomide cycles until first tumor progressionwas 6 (range, 0-51)
for theTTFieldsplustemozolomidegroupand5 (range,0-33) for
thetemozolomide-onlygroup; themediandurationofTTFields
treatmentwas8.2months (range,0-82months), 51%(n = 237)
of patients continued TTFields after the first progression.
Efficacy End points
After a median follow-up of 40months (IQR, 34-66months),
andaminimumfollow-upof24months, theprimaryendpoint
of median progression-free survival was 6.7months (95% CI,
6.1-8.1months) for patients treated with TTFields plus temo-
zolomide vs 4.0months (95%CI, 3.8-4.4months) for patients
treated with temozolomide alone, for a proportional hazard
ratio (HR) of 0.63 (95% CI, 0.52-0.76; P < .001; stratified log-
ranktest;Figure2A).For thesecondaryendpointofoverall sur-
vival, the median survival duration from randomization was
20.9months (95% CI, 19.3-22.7months) in the TTFields plus
temozolomidegroupvs 16.0months (95%CI, 14.0-18.4months)
in the temozolomide-onlygroup,proportionalHRof0.63 (95%
CI, 0.53-0.76; P < .001; stratified log-rank test; Figure 2B).
In exploratory analyses, the percentage of patients alive
at 2 years from randomization was 43% (95% CI, 39%-48%);
at 3 years, 26% (95% CI, 22%-31%), and at 5 years, 13% (95%
CI,9%-18%) in theTTFields plus temozolomide group and for
the temozolomide-onlygroupat2yearswas31%(95%CI,25%-
38%; P < .001); at 3 years, 16% (95% CI, 12%-23%; P = .009);
and at 5 years, 5% (95% CI, 2%-11%; P = .004). Progression-
free survival at 6months was 56% (95%CI, 51%- 61%) for pa-
tients treatedwithTTFieldsplus temozolomideand37%(95%
CI, 30%-44%) with temozolomide only (P < .001) (Table 2).
An exploratory Cox proportional hazards model adjust-
ing for Karnofsky performance score,MGMTpromotormeth-
ylation status, geographic region, age, tumor location, and
extentof resectionwereconsistentwith the findingsof thepro-
gression-free andoverall survival analyses. The following fac-
torswereassociatedwith longeroverall survival:TTFieldsplus
temozolomide treatment (HR, 0.63; 95% CI, 0.53-0.76;
P < .001), female sex (HR, 0.76, 95%CI, 0.63-0.92; P = .005),
methylated MGMT promoter (HR, 0.50; 95% CI, 0.41-0.62;
P < .001), younger age (as a continuous variable; HR, 0.978
per year;95%CI,0.969-0.985;P < .001) andhigherKarnofsky
performance score (as a categorical variable in 10 point incre-
ments; P < .001). Patients with frontal tumors had non-
significantly longer survival (HR = 0.82, CI0.67-1.01,P = .061).
Country of treatment and extent of resection were not
Figure 2. Kaplan-Meier Survival Curves for Patients Included in the Final Analysis in the Intent-to-Treat Population
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1.4 Glioma epigenetics: From subclassification to novel treatment options  
This chapter comprises a published review in the peer-reviewed journal Semi-
nars in Cancer Biology. My contribution included writing parts on the Histone code, 
Chromatin organization, Targeting the glioma epigenome; designing and drawing 
figures 2 and 3, as well as editing of the manuscript. 
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A B S T R A C T
Gliomas are the most common malignant primary brain tumors, of which glioblastoma is the most malignant
form (WHO grade IV), and notorious for treatment resistance. Over the last decade mutations in epigenetic
regulator genes have been identiﬁed as key drivers of subtypes of gliomas with distinct clinical features. Most
characteristic are mutations in IDH1 or IDH2 in lower grade gliomas, and histone 3 mutations in pediatric high
grade gliomas that are also associated with characteristic DNA methylation patterns. Furthermore, in adult
glioblastoma patients epigenetic silencing of the DNA repair gene MGMT by promoter methylation is predictive
for beneﬁt from alkylating agent therapy. These epigenetic alterations are used as biomarkers and play a central
role for classiﬁcation of gliomas (WHO 2016) and treatment decisions. Here we review the pivotal role of
epigenetic alterations in the etiology and biology of gliomas. We summarize the complex interactions between
“driver” mutations, DNA methylation, histone post-translational modiﬁcations, and overall chromatin organi-
zation, and how they inform current eﬀorts of testing epigenetic compounds and combinations in preclinical and
clinical studies.
1. Introduction
Gliomas are among the most common primary brain tumors in
adults and account for over 70% of malignant brain tumors, of which
glioblastoma is the most common and most malignant (World Health
Organization [WHO] grade IV) with an incidence rate of 3.2 per 100
000 population [1]. The median survival is less than 2 years with the
current standard of care of maximal safe resection, followed by com-
bined radio-chemotherapy with the alkylating agent Temozolomide [2]
that may be modestly improved with the addition of Tumor Treating
Fields [3]. Glioblastomas are notorious for resistance to therapy, and
despite numerous eﬀorts, the addition of targeted agents against genetic
or biological hallmarks of gliomas have largely failed [4]. Lower grade
gliomas (LGG) WHO grade II and III are less common and aﬀect
younger patients. They have a better prognosis and show some sensi-
tivity to therapy that both depend on the molecular subtype [5,6]. After
resection LGG patients may ﬁrst just be followed according to a “wait
and see” strategy that depends on clinical and molecular risk factors,
before entering treatment with diﬀerent schemes of radio- or che-
motherapy, or a combination thereof [6–8]. The optimal therapy is
debated, however treatment related eﬀects on cognitive function re-
quire risk-adapted (molecularly driven) treatment strategies, given that
LGG patients may live more than 15 years [9].
2. Epigenetics of glioma
2.1. Epigenetic subtypes of gliomas
Insights into the molecular landscape of diﬀuse gliomas have re-
vealed characteristic genetic and epigenetic proﬁles which have clar-
iﬁed their etiologic evolution [5,10–16] and allowed their classiﬁcation
into distinct molecular subtypes that have been integrated into the
2016 WHO classiﬁcation (Fig. 1) [17]. Mutations in the epigenetic
modulator genes isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2), and in
the histone genes H3F3A or HIST1H3 B have become key biomarkers
for tumor classiﬁcation and emphasize the important role of epigenetic
alterations as drivers in the evolution and biology of gliomas
[10,12,18–20].
A point mutation in IDH1 or IDH2 (IDHmt) is characteristic for
lower grade gliomas (WHO grade II/III), which are most prevalent in
young adults. IDHmt gliomas are further subdivided into two major
subtypes: oligodendrogliomas, with codeletion of chromosomal arms
1p/19q (1p/19q codel) that are usually associated with an activating
mutation in the promoter of TERT, and astrocytomas, without 1p/19q
codel. The latter are almost always associated with a mutation in TP53,
and a mutation in ATRX that leads to loss of its nuclear expression, and
diagnostically can be determined by immunohistochemistry [20]. Low
grade gliomas without IDH mutation are termed IDH wild-type (IDHwt)
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astrocytomas and are considered a provisional entity by the 2016 WHO
classiﬁcation. Upon further genetic analyses they may be classiﬁed into
other entities [21]. In glioblastomas IDHmt are infrequent (< 10%)
[10], and are usually observed in younger patients whose tumors may
have progressed from an IDHmt non-codeleted lower grade glioma
WHO grade II or III [22]. The histone mutation H3K27 M is char-
acteristic for pediatric midline high grade glioma and the H3G34R/V
mutation for hemispheric high grade glioma in children and young
adults [23]. Most interestingly, these epigenetic driver mutations are
associated with characteristic DNA methylation proﬁles, display char-
acteristic age distributions and tumor locations that is suggestive of
brain development related associations and are considered diﬀerent
diseases Fig. 1 [12,23].
2.2. DNA methylation
The most commonly studied epigenetic alterations in cancer com-
prise changes in DNA methylation, in particular methylation at the 5th
position of cytosines at CpG sites, resulting in 5-methylcytosine, also
known as the “ﬁfth base” of DNA. There are several DNA methyl-
transferases involved in DNA methylation, of which all use S-adenosyl-
L-methionine as source of methyl groups. DNMT1 preferentially me-
thylates hemi-methylated DNA and is responsible for maintenance of
DNA methylation patterns during replication, while DNMT3A,
DNMT3B, and DNMT3L act on unmethylated DNA and are responsible
for de novo methylation [24,25]. DNA demethylation involves the ten-
eleven translocation family of enzymes TET(1–3) that convert 5mC to 5-
hydroxymethylcytosine (5hmC) [26]. Additional epigenetic DNA
modiﬁcations are known, however, their identiﬁcation is technically
more challenging and their function is less well studied [27–29]. Cancer
development in general is associated with global DNA demethylation
(hypomethylation) aﬀecting intergenic regions, DNA repetitive se-
quences, gene bodies, including regulatory sequences; and aberrant de
novo methylation of CpG islands (hypermethylation) in promoter re-
gions of tumor suppressor genes [reviewed in [30]]. CpG islands refer
to regions with high density of CpGs within a sequence and are often
located in the regulatory region of promoters and are unmethylated in
non-cancerous tissue [31]. Epigenetic gene silencing following CpG
island methylation is mediated through methyl-CpG-binding domain
(MBD) proteins such as MECP2 that recruit histone-modifying and
chromatin-remodeling complexes to the methylated sites. DNA methy-
lation proﬁles of cancer are highly characteristic and retain some traits
of cell of origin. They have been successfully employed for re-deﬁning/
reﬁning classiﬁcation of brain tumors [12,32,33] or to determine the
origin of metastasis of unknown primary cancer [34]. Most of the
aforementioned studies reviewed here have been performed on the
Illumina DNA methylation BeadChip platform that interrogates
genome-wide DNA methylation and allows in addition gene copy
number analysis. Hence, there are multiple eﬀorts to develop molecular
classifying algorithms based on data derived on the Illumina DNA
methylation platform for WHO classiﬁcation of brain tumors (e.g. The
Heidelberg platform for next generation neuropathology can be used at:
MolecularNeuropathology.org) [35]. Aberrant methylation of CpG is-
lands in gene promoters leads to gene silencing aﬀecting cancer re-
levant pathways associated with the hallmarks of cancer [36]. In glio-
blastomas activation of the WNT pathway is mediated by aberrant
promoter methylation of multiple negative regulators, such as the gene
encoding the WNT inhibitory factor 1 (WIF1) or the family of secreted
frizzled-related proteins (sFRPs), dickkopf (DKK), and naked (NKDs)
[37,38]. Similarly, negative regulators of the Ras pathway are silenced,
such as the Ras association (RalGDS/AF-6) domain family member
RASSF1A [39].
2.3. The glioma CpG Island methylator phenotype associated with IDH1 or
IDH2 mutations
Gliomas with mutations in the metabolic genes IDH1 or IDH2 dis-
play a striking signature of DNA hypermethylation that is completely
diﬀerent from IDHwt gliomas, and has been termed Glioma CpG Island
Methylator Phenotype (G-CIMP) [11]. This fairly recent discovery has
indicated a novel driver mechanism in tumor development, conse-
quently IDHmt gliomas are now considered a diﬀerent disease as re-
ﬂected in the WHO 2016 classiﬁcation [17]. IDH mutations are early
lesions in the development of gliomas and cluster in the substrate
binding site of these enzymes, at codon 132 of IDH1 or codon 172 of
IDH2, respectively [40,41]. These mutations are always heterozygous
and confer a gain of function that favors a neomorphic reaction cata-
lyzing the conversion of α-ketoglutarate into D-2-hydroxyglutarate
(2HG) [41]. 2HG acts as a so-called oncometabolite by accumulating to
high concentrations that inhibit α-ketoglutarate-dependent enzymes. α-
Ketoglutarate-dependent enzymes comprise epigenetic modiﬁers such
as the enzyme TET2 involved in DNA demethylation or the lysine-
speciﬁc histone demethylase KDM2A [28,29,42–45]. However, α-ke-
toglutarate-dependent enzymes are also involved in other cellular
functions that are inhibited by 2HG, such as the DNA repair enzymes of
the ALKBH family, thereby altering response to chemotherapy [46], or
HIF1α regulating proteins, aﬀecting hypoxia sensing/signalling [47].
Obviously, the cell metabolism is seriously disturbed. Respective vul-
nerabilities have been identiﬁed and proposed as treatment opportu-
nities [45,48]. Similarly, acute myeloid leukemia (AML) display CIMP
in presence of a mutation in IDH1 or IDH2, with a preference for IDH2,
or a mutation in TET2. These mutations are mutually exclusive, and
Fig. 1. Major genetic and epigenetic subgroups of
gliomas. Characteristic epigenetic alterations are
written in bold. CHR, chromosome; H3, histone 3; G-
CIMP, glioma CpG island methylator phenotype.
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have been shown to preclude hematopoietic diﬀerentiation [44]. These
insights have contributed to the elucidation of the underlying me-
chanisms of CIMP. IDH mutations are considered the drivers for the
development of G-CIMP through the production of the oncometabolite
2HG that among other eﬀects mediates DNA hypermethylation through
inhibition of TET2 [44,49]. Moreover, IDHmt gliomas regardless of
tumor grade display a distinct immune phenotype characterized by
reduced expression of immune response signatures and by less in-
ﬁltration of tumor-associated immune cells [50–52]. This may be
mediated by various mechanisms, including G-CIMP associated hy-
permethylation of immune response related genes in the tumor, as
shown recently for CD274 (PD-L1) in IDHmt glioma [50], and by down-
regulation of leukocyte chemotaxis [51,52]. Altogether the plethora of
G-CIMP associated silenced genes, aﬀecting multiple cancer relevant
pathways, may hold opportunities for novel therapeutic approaches.
2.4. Clinically relevant epigenetic biomarkers
2.4.1. IDH status
Determination of the IDH mutation status is key for integrated
glioma classiﬁcation. An antibody speciﬁc for the most common mu-
tant, IDH1R132H that accounts for > 90% of all IDH mutations in
gliomas, facilitates diagnosis [40,53]. Alternatively, the associated G-
CIMP status can be easily determined based on the characteristic DNA
methylation proﬁle [11,12]. The oncometabolite 2HG can be detected
in patients by magnetic resonance spectroscopy and may be used for
longitudinal follow-up of patients, although this has not reached the
clinic yet [54,55]. The reliable measurement of 2HG in easily accessible
body ﬂuids is hampered by the blood brain barrier and has not yielded a
useful clinical test [56]. In IDHwt glioma of brain midline structures of
young adults, a histone H3K27M mutation needs to be considered,
which can be detected by immunohistochemistry with a H3K27M-
speciﬁc antibody [20].
2.4.2. MGMT promoter methylation status predictive biomarker in
glioblastoma
The DNA repair gene O6-methylguanine-DNA methyltransferase
(MGMT) is the most prominent epigenetically silenced gene in gliomas
[57–59]. In glioblastomas promoter methylation of MGMT is predictive
for beneﬁt from the alkylating agent temozolomide, as shown in several
phase III clinical trials, and the MGMT methylation status has become
the ﬁrst predictive biomarker in neuro-oncology [57,60–63]. MGMT
repairs the most toxic lesion, O6-methylguanine, induced by alkylating
agents, thereby blunting the treatment eﬀects. This is reﬂected by the
fact that patients with an unmethylated MGMT basically do not proﬁt
from the addition of temozolomide concomitant and adjuvant to
radiotherapy [57]. Routine determination of the MGMT status allows
for stratiﬁed treatment, and is used for selecting glioblastoma patients
for clinical trials omitting temozolomide in the experimental arm
[64–66]. The role of the MGMT methylation status on beneﬁt from
temozolomide in IDHmt lower grade gliomas is less clear [6], although
most (> 80%) show methylation at the MGMT promoter, probably as
part of G-CIMP [67]. However, unlike glioblastomas who usually lose
one copy of chromosome 10 on which MGMT resides, IDHmt lower
grade gliomas usually retain both copies and MGMT may not be com-
pletely silenced, resulting in residual repair capacity of MGMT con-
tributing to resistance to temozolomide therapy [68]. The most com-
monly used tests to determine the MGMT methylation status employ
methylation speciﬁc PCR [69], as reviewed elsewhere [61]. A MGMT
status classiﬁer (MGMT-STP27) is available for samples analyzed on the
Illumina DNA methylation platform (HM27 K, HM450 K, EPIC) [68,70]
and is widely used, including in clinical trials [6,13,71].
2.5. Histone code
The DNA molecule is packed in the nucleus of the cell by anchoring
proteins called histones. The formed complex of DNA and 8 histone
components of the nucleosome is referred to as chromatin. The chro-
matin is the essential environment through which transcription factors
and signalling pathways alter gene activity. Histones serve not only for
spatial organization of the DNA double helix, but also exhibit covalent
marks that orchestrate chromatin accessibility. Each of the 8 core his-
tones has a N-terminal tail hanging from the nucleosome that is sub-
jected to multiple post-translational modiﬁcations at speciﬁc residues,
comprising methylation, acetylation, sumoylation, ubiquitination,
phosphorylation, and others. In fact, over 500 distinct histone mod-
iﬁcations have been described, whereas the function of only a fraction
of them has been studied (reviewed in [72]). The histone marks are
recognized by a class of epigenetic proteins called readers, which in
concert with recruited proteins remodel particular genomic regions to
modulate target gene expression. The histone marks may be removed
by erasers and added by writers, thereby dynamically regulating the
chromatin code [73]. Active genes have been associated with tri-me-
thylation of lysine 4 (H3K4me3) and acetylation of lysine 9 (H3K9ac),
while inactive genes may be decorated with H3K9me3 and H3K27me3.
However, many active and inactive genes have overlapping patterns of
histone modiﬁcations. In fact bivalent histone marks are a hallmark of
embryonic stem cells (H3K27me3/H3K4me3) that keep genes in a
poised state for rapid changes and may predispose important regulatory
genes to inactivation by aberrant DNA hypermethylation, resulting in
malignant transformation and tumor progression [74].
A recent study using the TCGA GBM and LGG datasets exposed that
at least one of a set of 36 genes involved in chromatin organization was
targeted by genetic alterations in 54% of gliomas [16]. Interestingly,
most gliomas with alterations in this set of genes belonged to the mo-
lecular subgroup of IDHmt non-codeleted gliomas (n = 230, 87%)
[16]. Among the genes predicted to be potential glioma drivers, several
have epigenetic functions, such as ATRX (n = 226 mutations, 25% of
all cases), SETD2 (n = 24, 1%), ARID2 (n = 20, 1%), DNMT3A
(n = 11, 1%), SMARCA4 (n = 29, 3%), and ARID1A (n = 15, 1%)
[16].
In addition to histone modiﬁcations, genes coding for histones are
mutated in high grade glioma of children and adolescents [23]. Nearly
30% of pediatric high grade gliomas (WHO grades III and IV) harbor
point mutations at speciﬁc sites (K27M/I and G34R/V) of histone 3
(H3) gene variants (H3F3A, approximately 85%; HIST1H3B/C mutually
exclusive, 14%; and other more rare variants [75]). Of note, there are
thirty H3 variants in the human genome, and therefore the mutant al-
lele is present only in a minor proportion (7.6-17.6%) of the total H3
proteins [76]. Lysines (K) are key residues in histone tails subjected to
post-translational modiﬁcations by methylation or acetylation. There-
fore, substitution of K27 with methionine or isoleucine in H3 has an
impact on the epigenetic state of cells. Mechanistically it was shown
that mutated histones H3K27M/I directly bind to histone-lysine N-
methyltransferase (EZH2), thereby inhibiting the enzymatic activity of
the Polycomb repressive complex 2. The transgene encoding H3K27M
was demonstrated to eﬃciently reduce H3K27me3 levels in vitro and in
vivo [76]. Whereas the global levels of H3K27me3 are diminished in
H3K27M mutated gliomas, certain genes were shown to consistently
preserve their H3K27me3 mark [77].
2.6. Chromatin organization
Gene expression is also regulated by the overall 3D chromatin or-
ganization, which is modulated by several factors, including DNA me-
thylation and histone marks. The structure of the chromatin is com-
posed of loops or topology associated domains (TADs), which are
conserved evolutionarily, and are largely cell type invariant. The or-
ganization of TADs is responsible for placing the enhancer regions and
promoter regions into spatial proximity in order to activate target gene
expression. Originally TADs have been considered to be invariant
building blocks of chromosomes [78]. However, recent ﬁndings by the
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group of Bernstein suggested that the architecture of TADs is disturbed
in IDHmt glioma, allowing aberrant interactions between strong en-
hancers and oncogenes (Fig. 2). As a result of the reorganization of
TADs, the transcription of tumor promoting factors (e.g. oncogenes and
anti-apoptotic factors) is enhanced and promotes neoplastic growth
[79]. These observations were associated with the ﬁnding that IDH1mt
gliomas exhibit hypermethylation at cohesin and CCCTC- binding factor
(CTCF)-binding sites, which inhibits the binding of insulator protein
that is crucial for proper organization of TADs.
Overall, the functional impact of G-CIMP goes well beyond pro-
moter hypermethylation-related eﬀects and may be responsible for
disrupting chromosomal topology and allowing aberrant regulatory
interactions that may induce oncogene expression [79].
3. Targeting the glioma epigenome
Several diﬀerent approaches of targeting epigenetic alterations have
been or are being tested in clinical trials: those targeting mutant IDH
either by small molecule inhibitors, or as target for vaccination in the
respective patient population; and those targeting epigenetic modiﬁers
aﬀecting large parts of the epigenome such as BETi, HDACi, DNMTi,
and EZH2i (Fig. 3). Respective clinical trials, as available on clinical-
trials.gov, are summarized in Table 1.
3.1. Inhibitors of mutant IDH (mtIDHi)
Inhibitors of mutant IDH are currently tested in several trials for
patients with IDHmt gliomas with the aim to block the production of
the oncometabolite 2HG to normalize the function of α-ketoglutarate
dependent enzymes. Encouraging results from ﬁrst preclinical studies
suggested diﬀerentiation promoting eﬀects and attenuation of growth
in vitro and in vivo (subcutaneous xenografts) of glioma cells with an
endogenous heterozygous IDH mutation, while no appreciable changes
of overall DNA methylation was observed [80]. However, later reports
indicated that inhibition of IDHmt may not inhibit growth of IDHmt
glioma cells or propagation of orthotopic tumor xenografts [48,81]. On
the contrary, inhibition of IDHmt was suggested to promote the growth
of most tested IDHmt glioma lines in vitro [48]. A recent report adds to
this controversy, 10% (6/50) of a set of paired samples (ﬁrst resection/
recurrence) was found to lose the IDHmt allele upon malignant pro-
gression. Overall G-CIMP was preserved, however, exhibiting some al-
terations in DNA methylation [82]. The latter may overlap with “G-
CIMP-low” where progression related speciﬁc loss of methylation has
been postulated to enhance expression of cell cycle related genes as-
sociated with worse prognosis [16]. The progression related loss of the
IDHmt allele questions its importance for tumor maintenance and
consequently the suitability as single drug target. This question is also
of relevance for the vaccination trials targeting IDH1R132H, for which
encouraging preclinical studies have been presented [83]. Interestingly,
it has been suggested that reversing the inhibitory eﬀect of 2HG on
STAT1 mediated expression of IFN-γ–inducible chemokines may im-
prove the vaccination approach [51]. The complexity of the diﬀerent
eﬀects on tumor biology linked to targeting the IDHmt renders the
outcome predictions diﬃcult. Thus, the results of the clinical trials are
eagerly awaited.
3.2. EZH2 inhibitors (EZH2i)
EZH2 is an interesting target within the polycomb repressor com-
plex 2 (PRC2) in pediatric glioma, since the H3K27M mutation has been
Fig. 2. Chromatin dysorganization and histone mutations in glioma. (a) Cell insulator protein CTCF separates topologically associated domains, depicted as loops. Flavahan and others
showed that in IDH1mt glioma CTCF binding sites are often methylated reducing CTCF–DNA binding [78]. This allows aberrant associations between enhancers and the promoter regions
of oncogenes. (b) Histone genes are mutated in about 50% of gliomas in children and young adults. Majority of mutations (85%) are found in histone variant H3.3, and 14% are found in
variant H3.1. H3K27M and H3G34R/V mutations are associated with diﬀerent patient age, diﬀerent location of the tumor, and distinct methylation phenotype (reviewed in the text).
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shown to inhibit PRC2 activity [76]. The EZH2i Tazemetostat is cur-
rently tested in pediatric glioma with a gain of function mutation in
EZH2 or loss of function mutations in the chromatin remodeling com-
plex subunits SMARCB1 or SMARCA4 (Table 1). However, these mu-
tations are rare in pediatric gliomas [18,75,84].
Preclinical studies of the EZH2i Tazemetostat show a mixed picture.
While the EZH2i Tazemetostat was suggested to lack activity in pe-
diatric glioma cells in vitro independent of H3.3 mutations [85], a re-
cent study provided evidence that Tazemetostat may aﬀect growth of
primary H3K27M-positive glioma cells in presence of functional
p16INK4A [86].
Short-term EZH2 depletion in glioblastoma cells without H3 or IDH
mutations, has been associated with reduced proliferation [87], while
recent results suggest that prolonged EZH2 inhibition may cause a
switch in cell fate, enhancing proliferation and DNA damage repair,
resulting in tumor progression [88].
3.3. DNA methylation inhibitors (DNMTi)
Preclinical studies have suggested eﬃcacy of DNA methylation in-
hibitors (DNMTi) in in vitro and in vivo models of IDHmt glioma
[81,89]. However, this has not translated into successful treatments
with DNMTi in glioma patients, possibly because 5-Azacytidine and
Decitabine are S-phase-speciﬁc and have relatively short half lives [90].
The novel second-generation hypomethylating drug guadecitabine with
better pharmacodynamic characteristics is currently tested in a phase
III study in AML [91]. However, it remains controversial whether
general demethylation is desired in glioma, as unwanted proto-onco-
genes may be activated, and demethylation of the repair gene MGMT
may render glioblastomas resistant to alkylating agents that are part of
the standard of care. Interestingly, low dose demethylating agents im-
pact immune regulation and may induce innate immune response by re-
activating retroviruses [92,93].
3.4. Histone deacetylase inhibitors (HDACi)
The underlying rationale of using HDACi as cancer therapeutics is to
reverse dysregulated target gene expression by modulating histone
acetylation marks [94]. Dynamic regulation of the chromatin state is
mediated by mechanisms such as covalent modiﬁcation of chromatin,
which includes histone acetylation and methylation, and ATP-depen-
dent chromatin remodeling. Histone 3 lysine acetylation is a mark of
active enhancers that control the expression of associated distal genes.
Generally, exposure to HDACi results in hyperacetylation of histones,
which globally aﬀects gene expression.
Vorinostat has been tested in phase II trials of recurrent glio-
blastomas, ﬁrst as single agent that has shown good tolerability.
Moreover, the study also indicated that the drug aﬀected target path-
ways in glioblastomas [95]. Taken to the next step, vorinostat was
tested in combination with the protease inhibitor bortezomib that
however, in the dosing scheme used showed no eﬃcacy [96]. In newly
diagnosed glioblastoma the addition of vorinostat to the standard of
care of radiochemotherapy did not meet the primary endpoint of eﬃ-
cacy in a phase I/II trial. However, indications from molecular sub-
group analyses may provide criteria for future patient selection [97].
Fig. 3. Epigenetic inhibitors and drugs currently under investigation in preclinical glioma models and clinical trials. DNMT, DNA methylases; HDAC, histone deacetylase, BET, bro-
modomain and extra-terminal tail protein; EZH2, Enhancer of zeste homolog 2, histone-lysine N-methyltransferase; ac, acetylation; 3me, tri-methylation, 5mc, 5-methylcytosine; 5hmc, 5-
hydroxymethylcytosine.
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3.5. BET inhibitors (BETi)
Another way to target enhancer elements is to inhibit readers of the
acetylated histone tails (Fig. 3). Bromodomain and extra-terminal tail
(BET) proteins are chromatin readers, they recognize and bind to the
H3K9 and H3K27 acetyl marks, recruit mediator complex and promote
transcription of target genes. BET proteins were shown to be essential
for high-level expression of oncogenes. Moreover, BETi were demon-
strated to reduce the transcription of oncogenes by attenuating en-
hancer activity at so-called super-enhancers [98]. Super-enhancers are
referred to as large clusters of transcriptional enhancers driving ex-
pression of genes that control cell identity and disease including cancer
[99]. In an in vivo RNAi screen, testing chromatin regulators required
for survival of glioblastoma cells in an intact environment, BRD4 was
among the top hits [100]. Preclinical studies in orthotopic mouse
glioblastoma xenografts have reported eﬃciency of several BETi, such
as the tool drug JQ1, I-BET151, and OTX015 [101–103]. Moreover,
IDHmt primary glioma cells were reported to be very sensitive to BETi
JQ1 and GS-626510 with half-maximal inhibitory concentrations 1 000
times lower than the one of Temozolomide [104].
A phase IIa trial for dose optimization of OTX015 in recurrent
glioblastoma patients was terminated in 2015 due to lack of eﬃcacy in
this patient population [105]. Other BETi with diﬀerent pharmacoki-
netic properties are currently in preclinical evaluation.
3.6. Potential of epigenetic drugs in treatment resistance
The combinations of epigenetic drugs with conventional chemo/
radiation therapy or with targeted compounds are still in the early
stages of preclinical research in glioma. Recent reports suggested that
both conventional chemotherapy [106] and tyrosine kinase inhibitors
[107] may facilitate the growth of pre-existing resistant clones.
Importantly, these resistant clones were shown to be sensitive to epi-
genetic drugs. Dirks and co-workers have reported that Temozolomide-
resistant clones displayed epigenetic changes that rendered them sen-
sitive to the inhibitor of Menin-MLL (MI-2-2) [106]. Furthermore, the
group of Bernstein demonstrated that Dasatinib-tolerant persisters were
dependent on the H3K27me3 demethylases KDM6A/B and were
therefore highly sensitive to the KDM6A/B small molecule inhibitor
GSKJ4 [107]. Overall, the insights of these preclinical studies suggest
that epigenetic drugs combined with conventional therapy, such as
alkylating drugs or tyrosine kinase inhibitors may act synergistically to
eliminate refractory tumor cells and potentially inhibit the expansion of
resistant clones.
4. Conclusions
Discoveries of the last decade have completely changed our view on
the genomic and epigenetic landscape of human gliomas. Driver mu-
tations in epigenetic regulator genes have clariﬁed their etiology and
deﬁned molecular subtypes with distinct biology. Consequently, epi-
genetic biomarkers play now a central role in tumor classiﬁcation and
decision making for stratiﬁed therapies. A whole arsenal of epigenetic
drugs promises to target epigenetically deregulated pathways by in-
terfering on several levels. However, the complex interplay between
gene expression, DNA methylation, histone modiﬁcations, and chro-
matin organization presents challenges for rational trial designs.
Moreover, the dynamic epigenetic changes in response to therapy (re-
sistance) or the interaction with the tumor microenvironment yield
challenges and opportunities. At present a number of trials have been
initiated and await completion (Table 1). The insights from basic and
preclinical research, and ﬁrst clinical trials reviewed here, suggest that
single epigenetic agents are likely not suﬃcient, and molecularly in-
formed combinations with other epigenetic drugs, or other targeted/
Table 1
Ongoing clinical trials testing epigenetic drugs in gliomas.
Source, https://clinicaltrials.gov.
Drug Target Age group
(years)
Clinical trial identiﬁer* Trial phase Malignancy
IDH inhibitors
AG-881 mutant IDH1 and/or mutant
IDH2
18+ NCT02481154 I Glioma with IDH1 and/or IDH2 mutation
AG-120 (Ivosidenib) mutant IDH1 18+ NCT02073994 II Glioma with IDH1 mutation
AG-221 (IDHIFA, Enasidenib) mutant IDH2 18+ NCT02273739 I/II Glioma with IDH2 mutation
BAY1436032 mutant IDH1 18+ NCT02746081 I Glioma with IDH1 mutation
DS-1001b mutant IDH1 20+ NCT03030066 I Glioma with IDH1 mutation
IDH305 mutant IDH1 18+ NCT02381886 I Glioma with IDH1 mutation
IDH305 mutant IDH1 18+ NCT02977689 II Glioma grade II or III with IDH1 mutation
IDH1R132H peptide vaccine IDH1R132H 18+ NCT02454634 I Glioma grade III-IV with IDH1 mutation
IDH1R132H peptide vaccine IDH1R132H 18+ NCT02193347 I Recurrent glioma grade II withIDH1
mutation
IDH1R132H dendritic cell
vaccine
IDH1R132H 18–70 NCT02771301 safety Glioma with IDH1 mutation
EZH2 inhibitors
Tazemetostat mt and wt EZH2 1–21 NCT03155620 II Glioma with EZH2, SMARCB1, or SMARCA4
mutation
HDAC inhibitors
Valproic acid HDAC, class I and II 3–17 NCT03243461 III Pediatric glioma
Entinostat HDAC, class I 1–21 NCT02780804 I Recurrent childhood visual pathway glioma
Panobinostat (LBH589) HDAC, class I, II, and IV 2–21 NCT02717455 I Diﬀuse intrinsic pontine glioma
Vorinostat (SAHA) HDAC, class I and II 3–21 NCT01189266 I/II Diﬀuse intrinsic pontine glioma
Vorinostat (SAHA) HDAC, class I and II 0.5– 21 NCT02420613 I Diﬀuse intrinsic pontine glioma
Vorinostat (SAHA) HDAC, class I and II 18+ NCT00268385 I Glioma
Vorinostat (SAHA) HDAC, class I and II 3–21 NCT01236560 II/III Pediatric high grade glioma
Vorinostat (SAHA) HDAC, class I and II 18+ NCT00555399 I/II Glioblastoma
Belinostat HDAC, class I and II 18+ NCT02137759 II Glioblastoma
Vorinostat (SAHA) HDAC, class I and II 18+ NCT00731731 I/II Glioblastoma
DNMT inhibitors
5-Azacytidine (Vidaza) DNMT 1–21 NCT02940483 I Recurrent posterior fossa ependymoma
5-Azacytidine (Vidaza) DNMT 1–18 NCT03206021 I/Ib Recurrent ependymoma
5-Azacytidine (Vidaza) DNMT 18+ NCT02223052 I Glioblastoma
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conventional therapies will be required. Furthermore, the glioma me-
thylome, in particular in IDHmt/G-CIMP positive gliomas, still awaits
exploration for potential vulnerabilities of cancer relevant pathways
that may be amenable to speciﬁc treatments, beyond Temozolomide for
glioblastomas with MGMT promoter methylation. Further insights on
the eﬀects of epigenetic drugs on the modulation of the tumor immune
environment; and the exploration of 2HG- dependent metabolic vul-
nerabilities in IDHmt gliomas may provide additional opportunities. We
are just at the beginning of an exciting new era.
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1.5 BET inhibitors (BETi) in cancer 
1.5.1 BET proteins 
Bromodomain and extra-terminal tail (BET) proteins belong to a class of epi-
genetic proteins called “readers”, since their function is to recognize (or read) the 
acetylated Lysines on histone tails and promote the signal downstream. BET pro-
teins are a family of 4 proteins BRD2, BRD3, BRD4, and BRDT, which is only ex-
pressed in the testis. 
BET proteins are localized on the promoters and active enhancer elements, 
they recruit mediator complexes to promote target gene transcription. It was recently 
shown that enhancer elements are not functioning equally, on the contrary, out of a 
few thousands of enhancers in a human cell, a few hundred are nick-named super-
enhancers that are characterized by high binding of mediator complex and master 
transcription factors (Fig.1:4) (Hnisz et al., 2013; Loven et al., 2013; Whyte et al., 
2013). Super-enhancers are highly cell-type specific and were shown to drive cell 
identity (Whyte et al., 2013). In cancer super-enhancers were suggested to be re-
sponsible for high expression levels of oncogenes and anti-apoptotic factors (Loven 
et al., 2013).  
Figure 1:4. BRD4 inhibition re-
presses transcription of super-
enhancer driven oncogenes.  
In cancer cells super-enhancers are 
occupied by BRD4, mediator complex 
and master transcription factor regula-
tors. Loven and others showed that 
super-enhancers may drive transcrip-
tion of oncogenes, which can inhibited 
by BETi.  Adapted from graphical ab-
stract (Loven et al., 2013). 
 
	
	
	
	
1.5.2 The rationale behind using BET inhibitors in cancer 
BET inhibitors are certainly of interest for the disease called NUT midline car-
cinoma. There, the BRD4 locus (19p13.1) is fused to the locus of nuclear protein in 
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testis (NUT) (15q14), which forms a new in-frame transcript that is believed to be a 
driver event for this malignancy (Fig.1:5). When NUT midline carcinoma cells were 
treated with BETi JQ1, the cells were terminally differentiating and G1 arrested 
(Filippakopoulos et al., 2010); whereas in clinic partial remission was reported from 
phase I trials in NUT midline carcinoma patients (Massard et al., 2016; O'Dwyer et 
al., 2016; Stathis et al., 2016). 
Figure 1:5. Fusions of 
BRD3 or BRD4 with 
NUT in NUT midline 
carcinoma.  
The arrows point at the 
breakpoints where the 
fusions occur. Adapted 
from (Filippakopoulos et 
al., 2010).	
In several cancers genetic screens pointed out at BET proteins to be essential 
for tumour cell survival (Baratta et al., 2015; Marcotte et al., 2016; Zuber et al., 
2011). Some cancers were reported to exhibit high expression level BRD2 and 
BRD4 (Delmore et al., 2011; Marcotte et al., 2016). 
1.5.3 Response to BET inhibitors in the clinic 
There is a strong evidence of response to BETi in hematological malignan-
cies. In preclinical studies leukemia and B-cell lymphoma cell lines displayed cell-
cycle arrest and apoptosis when exposed to low concentrations of BETi (Berthon et 
al., 2016; Boi et al., 2015). Some leukemia patients responded well to BETi treat-
ment (2/41 complete remission, and 3/41 partial remission), whereas no biomarkers 
of response were identified in responders versus non-responders (Berthon et al., 
2016). Lymphoma patients showed responses similar to that of leukemia with 2/33 
complete remissions, and 1/33 partial remission. Whereas multiple myeloma patients 
included in the same trial did not show evidence of response (Amorim et al., 2016). 
One more trial testing a different BETi in Non-Hodgkin lymphoma patients reported 
2/44 complete remissions and 1/44 partial remission (Abramson et al., 2015). The 
mentioned clinical trials were phase I and therefore tested the compounds in a dose 
escalation setting with 3/10 (Massard et al., 2016) partial responses. So, the re-
sponse was limited to 20-30% of patients. Moreover, all the patients relapsed during 
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the treatment (O'Dwyer et al., 2016). A bigger study in a defined cohort of patients 
with confirmed NUT-BRD4 fusions should be done in order to address the efficacy of 
BETi in NUT midline carcinoma.  
In other solid cancers, reported results from clinical trials for BETi are more 
pessimistic with 1/36 prostate cancer with a partial response (Massard et al., 2016), 
and no evidence of response reported in lung cancer (Massard et al., 2016) and in 
GBM (Hottinger et al., 2016), the latter was in part performed in CHUV (OTX015 
drug). 
1.5.4 Reported clinical toxicities of BETi 
The toxicities with BETi are somewhat expected, since BET proteins are es-
sential for transcription; and both BRD2 and BRD4 knockout mice are embryonically 
lethal (Gyuris et al., 2009; Houzelstein et al., 2002; Shang et al., 2009). Moreover, 
mice treated with BETi were reported to lose their long-term memory (Korb et al., 
2015) and to develop autism-like syndrome (Sullivan et al., 2015). Lastly, male mice 
treated with BETi are infertile, since one of the BETi targets, BRDT, is essential for 
spermatogenesis (Matzuk et al., 2012). 
In the clinic, cancer patients treated with various BETi commonly exhibited 
thrombocytopenia, an abnormally low levels of platelets in the blood. The other re-
ported toxicities included anemia, headaches, fatigue, gastrointestinal tract toxicities, 
diarrhea and an increase of bilirubin (reviewed in (Stathis and Bertoni, 2017)). 
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1.6 Aims of the project 
Glioblastoma remains to be largely incurable with limited treatment options 
available. It has become clear that single agent drugs fail in clinical trials, and new 
strategies for combination therapies are urgently needed. In this project we aim at 
targeting enhancer elements, which are crucial for epigenetic regulation of gene ex-
pression, in GBM models in order to identify novel drug combination strategies. The 
project entailed: 
1. Characterization of cellular response to pharmacological BET inhibition in vitro 
2. Identification of gene expression signatures induced by JQ1 in an in vitro glio-
blastoma sphere model 
3. Validation of obtained signatures  
4. Prediction of compounds that can used in combination with BETi 
5. Testing the predicted drug combinations in vitro and in vivo 
1.7 Advantage of Glioma sphere cell lines (GS-lines) 
Most of the experiments in this project were performed with a 3D model of gli-
oblastoma GS-lines that were patient derived and established in our laboratory. GS-
lines grow in neurobasal medium without FBS and form cell clusters or glio-
maspheres. GS-lines represent a better model of GBM compared to regular adher-
ent cell lines for multiple reasons. First, GS-lines grow very invasively when injected 
orthotopically in immunocompromised mice. Moreover, GS-lines conserve certain 
tumour stem-cell properties, and EGFR amplification that is normally present in 50% 
of GBMs, but for unknown reasons is lost among adherent GBM models (Balvers et 
al., 2013). Moreover, GS-lines represent the molecular subtypes of GBM. The exper-
iments were performed with 6 GS-lines, and every experiment was performed in LN-
2683-GS. Importantly, LN-2683-GS was derived from a recurrent GBM, the patient 
was treated with TMZ/RT-TMZ in first line, hence representing a “naturally resistant” 
model (Table 6:1). 
		
 Materials and Methods Chapter 2
2.1 Cell culture  
Glioblastoma derived sphere lines (GS) LN-2207-GS, LN-2683-GS, LN-2540-
GS, LN-2669-GS were established in our laboratory, molecularly characterized 
(Bady et al., 2012; Kurscheid et al., 2015; Sciuscio et al., 2011), and authenticated 
(Bady et al., 2012). The corresponding GEO accession numbers are GSE60274, 
GSE108098, and GSE104291 for DNA methylation, aCGH, and gene expression 
data, respectively. LN-3704-GS, LN-3708-GS, and LN3397 were recently derived in 
our laboratory (authentication pending). LN-18, LN-428 were established in our la-
boratory (Bady et al., 2012; Ishii et al., 1999). U87MG, PEO1, and OVCAR3 origi-
nate from ATCC. BS-153 originates from the laboratory of Adrian Merlo. U87MG, 
LN-18, LN-428, and BS-153 were grown in DMEM Glutamax (Gibco) with 5% FBS 
(Hyclone or PAA). Ovarian cancer cell lines OVCAR3 and PEO1 were grown in 
RPMI (Gibco) supplemented with 10% FBS (PAA).  
GS-lines were cultured under stem-cell conditions in Dulbecco’s modified Ea-
gle medium/F12 containing B27 supplement and 20ng/ml of epidermal growth factor 
(EGF, Peprotech) and 20ng/ml of fibroblast growth factor (FGF, Peprotech). For set-
ting up experiments, the spheres were separated into a single cell suspension by 
treatment with Accutase (Gibco), followed by separation with fire treated Pasteur 
pipettes with cotton plugs for a maximum of 10 minutes. The cell counter (EVE) was 
used to count live cells using tryptan blue exclusion assay. The cell density used was 
1 M of live cells per 9 ml of B27 media unless stated otherwise. 
For Interferon priming of GS-lines, the interferon-alpha (Peprotech or PBL as-
say Science) was added to the final concentration of 1000 units/ml, and interferon-
gamma (GenWay Biotech) to the final concentration of 20 ng/ml. B27 medium was 
added to respective control dishes. 
Mycoalert kit (Lonza) was used for routine mycoplasma contamination testing. 
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2.2 JQ1 and TSA treatment  
(+)-JQ1 and its inactive enantiomer (-)-JQ1 (ApexBio Technology LLC) were 
dissolved to 10mM in DMSO, stored at -20 C aliquoted. Trichostatin A (Sigma) was a 
ready-made solution supplied as 5mM in DMSO and stored aliquoted at -20C. The 
drugs were added to the GS-lines cells 3 days after seeding to allow the sphere for-
mation. For long (10 days) exposures, the media and drugs were refreshed on day 6. 
2.3 Senescence-associated β-Gal assay 
120,000 of U87MG cells for JQ1, and 80,000 cells for DMSO per well were 
seeded in 12-well plates. The next day 1µM (+)-JQ1, (-)-JQ1 or DMSO was added 
for 72 hours. Plates were stained for the activity of β-Gal using the β-
Galactosidase staining Kit (Biovision) according to manufacturer’s instructions, and 
incubated overnight at 37°C. Imaging of 5 random fields per condition was performed 
by stereomicroscope (Leica M205FA). The quantification of proportion of β-Gal pos-
itive cells was done manually with ImageJ by two researchers independently. 
2.4 Immunofluorescence of GS-lines 
Single cells of LN-2683-GS were seeded at density 500,000 cells per 3ml, and 
one day later, 1µM JQ1 or DMSO was added. The spheres were fixed and permea-
bilized 10 day after drug addition for 3 hours at 4°C in a fixing/permeabilizing buffer 
(4% Formaldehyde, 1% Triton X-100). The spheres were then washed in 1X 
PBS/0.1% Tween and blocked in blocking buffer (PBS/5% donkey se-
rum/0.1%Tween) for 60 minutes at room temperature. Incubation with primary anti-
bodies was done overnight at 4°C in blocking buffer with the anti-TUJ1 antibody (Cell 
Signalling, 1:400). The spheres were then washed once in PBST and incubated with 
fluorochrome-conjugated anti-rabbit Alexa 647 (Abcam, 1:500). Then the spheres 
were washed with PBS and resuspended in 15 µl of mounting medium Vectashield 
containing DAPI (Vector), and mounted on glass slides. Image acquisition was per-
formed with 64x objective of Leica SP5 tandem confocal microscope. For the figure 
brightness and contrast of images were adjusted equally in JQ1 and DMSO in Pho-
toshop CC (2015) to increase visibility for the reader. 
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2.5 Cell viability assay 
2.5.1 Cell viability assay of adherent GBM cell lines 
4000 cells/well of LN-18, LN-428, and U-87MG; or 4500 cells/well of BS-153 
were seeded in 100 µl of complete medium. Next day (+)-JQ1, (-)-JQ1 was added to 
the plate as a 10-point serial dilution 1:3 starting form 30 µM. For 0% viability control 
cytotoxic concentration of of Actinomycin D (1 µg/ml) was added, and for 100% via-
bility just DMSO. 72 hours later medium was aspirated and 10% Cell Titer Blue in 
complete medium was added. Plates were incubated for 1 hour at 37C. And cell via-
bility was measured with Tecan plate reader. The data was analyzed with Graphpad 
Prism 6 using drug-response curve fitting algorithm with variable Hill slope.	
2.5.2 Cell viability assay of GS-lines 
3750 cells of LN-2207-GS, LN-2540-GS, and LN-2683-GS per well of 96-well 
plate were plated in 75 µl in B27 media. 3 days after seeding JQ1, (-)-JQ1 was add-
ed to the plate in 75 µl. 10-point serial 1:2 dilution starting with 30 µM was used. Af-
ter 72 hours 20 µl of Cell Titer Blue was added and incubated for 4 hours at 37C. 
Fluorescence was measured by Tecan plate reader and data was analyzed in 
GraphPad Prism 7. The wells without drugs were set to 100% viability and wells 
treated with lethal concentration of Actinomycin D (1µg/ml) were set to have 0% of 
the viability. A curve-fitting algorithm with variable Hill slope was applied to the inten-
sity values to derive IC50 values. The experiment was repeated at least 3 times for 
each GS-line. 
2.6 Drug combination assay 
3750 cells of LN-2683-GS and LN-3708-GS per well of 96-well plate were 
plated in 75 µl in B27 media. 3 days after seeding the drugs were added to the plate 
in 75 µl four each drug. 7-point serial 1:2 dilution starting with 20 µM was used. The 
drugs were added as in a chessboard pattern (8 by 8), so that every concentration of 
JQ1 is tested with every concentration of TSA. DMSO was used as a control. 
After 5 days 22.5 µl of Cell Titer Blue was added and incubated for 4 hours at 
37 C. For 10 days the cells were set as above, but JQ1 and TSA were added at a 
serial dilution starting from 2µM. After 5 days the plate was centrifuged for 5 min at 
300g and 150 µl of the supernatant was removed from each well. JQ1 and TSA were 
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added in 75 µl of B27 each in the corresponding concentration. Fluorescence was 
measured with Tecan plate reader and data was analyzed in R. The package syner-
gyfinder was used to access the combination score (combination of Lowe and Bliss 
combination indexes) (He et al., 2016). The experiment was repeated at least three 
times for each GS-line and both time points. 
2.7 Neurosphere Formation Assay 
The protocol was adapted from (Cheng et al., 2013). Briefly, single cells were 
seeded into a 48-well plate with 100 cells per well in 100µl F12/B27 medium contain-
ing EGF and FGF (LN-2207-GS, LN-2540-GS, LN-2683-GS) and with 1000 cells per 
well for LN-2669-GS. Then, JQ1 diluted in 100µL F12/B27 to a final concentration of 
0, 0.25, 0.5, 1, 2 or 4 µM was added, with 4 replicates per condition. EGF and FGF 
to a final concentration of 20ng/ml in 2µl F12/B27 were added to each well on day 8 
and 15. The spheres with a diameter exceeding 50µm were counted after 14 and 21 
days. The experiment was repeated 3 times. 
2.8 RNA Extraction, qRT-PCR 
Total RNA was isolated from the cell lines with the ReliaPrepTM RNA cell mini-
prep kit (Promega, WI, USA). mRNA from xenografts was isolated with RNeasy Mini 
Kit (Qiagen). The quantity and quality of the extracted RNA was assessed by 
Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA) and by Fragment Analyzer 
for xenografts samples. DNAse treatment was performed with RapidOut DNA Re-
moval Kit (Thermo Fisher Scientific). 
cDNA was synthesized with PrimeScript RT reagent kit (Takara, Kyoto, JPN). 
Real-time qPCR was done using the Kapa Sybr® Fast Universal qPCR kit (Kapa 
Biosystems, MA, USA), on a Rotor Gene 6000 real-time PCR system (Qiagen, Ven-
lo, NLD). The qPCR conditions were the following: 95°C (100s) followed by 40 cycles 
at 95°C (3s) to 60°C (20s). The quality of the products was controlled with the melt-
ing curve. The expression levels were normalized to GAPDH, and to geometrical 
mean of hGAPDH and C1orf43 for cDNA derived from mouse xenografts. The pri-
mers were designed with Universal Probe Library System Assay Design (Roche). 
Gene-specific primers used in this study are in Table 6:2. 
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2.9 Protein Extraction 
Cells were collected by centrifugation for GS-lines or by scraping for adherent 
cells, washed with PBS, snap-frozen. The pellets were lysed in RIPA buffer (50mM 
Tris-HCL, 150mM NaCl, 2mM EDTA, 1mM EGTA, 1% Triton, 0.5mM Phenylmethyl-
sulfonyl fluoride), supplemented with protease inhibitor cocktail (Roche) and PhoS-
TOP (Phosphatase Inhibitor Cocktail, Roche). The pellets were lysed by passing 
them 5 times through a 25-gauge needle. The proteins were then separated from the 
cell debris by centrifugation at 15,000g for 15 minutes at 4°C. For Nuclear and Cyto-
plasmic fractions extraction NE-PER kit (Thermo Scientific) was used with the follow-
ing modifications. Nuclei were lysed in 30µl NER buffer supplemented with protease 
inhibitor cocktail (Roche) and PhoSTOP (Phosphatase Inhibitor Cocktail, Roche) and 
sonicated on ice at 30% amplitude for 5 sec or until homogenized with Bandelin 
Sonoplus Sonifier with 2.5mm needle. Protein quantification was done using the 
Bradford assay (Bio-Rad, Hercules, USA) with BSA as a standard in a 96-well plate. 
2.10 Western Blot 
Western Blot was performed as described previously (Lenain et al., 2015). 
Briefly, 20-40 µg of protein extracts were separated on SDS polyacrylamide gradient 
(4-20%, Biorad) or homemade gels of desired concentration. The proteins were then 
transferred to nitrocellulose 0.45µm blotting membrane (GE, Healthcare Life Scienc-
es or Biorad). Equal loading was verified with Ponceau S (Sigma) and membranes 
were blocked for 1 hour in 5%BSA (ApexBio) or 5% non-fat skimmed milk (Migros) at 
room temperature. The membranes were probed in 5% milk or 5% BSA overnight at 
4°C with the following antibodies: anti-BRD4 (Bethyl Laboratories, A301, 1:7,000), 
anti-PARP (Cell Signalling, #9542, 1:5000), anti-α-tubulin (Sigma, T5168, 1:10,000), 
anti-C-MYC (Abcam, #32072, 1:10,000), anti-TUJ1 (Cell Signalling, #5568, 
1:10,000), anti-GAPDH (Sigma, #G9545, 1:10,000), anti-Histone H3 (Abcam, 
ab1791, 1:1,000), anti-PD-L1 (Cell Signalling, #13684, 1:2,000), anti-STAT1 (Cell 
Signalling, #9172, 1:1,000), anti-pSTAT1 (Cell Signalling, 7649, 1:1,000), anti-
Vinculin (Sigma, V91131, 1:4,000). 
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2.11 Cell cycle analysis 
Spheres were dissociated, and single cells were seeded into a 6-well plate 
with 0.3M cells per well (LN-2207-GS) and 0.45M cells per well (LN-2683-GS), in 
3ml F12/B27 supplemented with 20 ng/ml of EGF and FGF. (+)-JQ1, (-)-JQ1 or 
DMSO diluted in 1ml F12/B27 was added to the wells on day 4 for a final concentra-
tion of 1µM. Cells were incubated with BrdU for 1 hour at 37C on day 5 and 10 after 
drug addition. For the condition “5 days on drug / 5 days off drug”, the medium of the 
cells was changed on day 6 to a normal F12/B27 medium. The cells were stained 
with anti-BrdU antibody conjugated with FITC and 7-AAD using BD PharmingenTM 
BrdU Flow Kits (BD Biosciences). Acquisition was done with FACS (Calibur) on up to 
1M cells. Cell cycle distribution was analyzed with FlowJo software (FlowJO LLC, 
version 7). 
2.12 RNA sequencing and differential expression analysis 
LN-2683-GS cells were seeded at a density of 0.35 M per 6-cm petri dishes in 
3 ml of B27. 2 days after (+)-JQ1 or DMSO were added to a final concentration of 
1µM. The cells were lysed in RLT buffer and snap-frozen at 4, 12, 24, and 48 hours. 
Untreated cells in quadruplicate at baseline (0 hours) were harvested directly without 
treatment. 
For RNA sequencing Qiagen RNeasy Mini Kit was used according to the 
manufacturer's instructions. Quality of RNA was assessed by Fragment Analyzer. 
The library preparation was performed with TruSeq Stranded Total RNA Library Prep 
Kit (Illumina). Samples were multiplexed as 7 samples per lane and ran in single 
read mode on Illumina HiSeq 2500. The preprocessing of RNAseq data was per-
formed following the standard pipeline and recommendations from bcbio-nextgen 
(version 0.8, http://bcbio-nextgen.readthedocs.org/en/latest/). After trimming of 
adapter and polyA; and standard quality control checking, the alignment to human 
reference genome (assembly GRCh37) was performed by STAR aligner (version 
2.4.0). Differential Expression was performed with edgeR package (version * 3.12.0) 
using model with full interaction between treatment and time. Genes with Bonferroni 
adjusted P-values<0.001 were considered differentially expressed. Gene set enrich-
ment analysis was performed with PGSEA package (version* 1.44.0) and GAGE 
package (version * 2.20.1) using and The Molecular Signatures Database (MSigDB 
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version 5, Broad Institute). Hallmark gene set H collection was used for primary as-
sessment and the results from running enrichment on all 8 collections are reported 
here. The gene sets with FDR adjusted P-value <0.05 were considered significant. 
2.13 Analysis of reproducibility of cluster G12 in TCGA dataset 
To estimate the similarity among the distance matrices of NCHaffy (Murat et 
al., 2008), TCGAaffy, and TCGArnaseq (Brennan et al., 2013) expression data 
frames, we used the RV-coefficient (Escoufier, 1973). Pairwise RV coefficient per-
mutation tests were performed on the distance matrices with R package ade4 
(Chessel et al., 2004). 
2.14 Analysis of CD274 expression in glioma cell lines 
To assess the expression of CD274 in glioma cell lines we used affymetrix 
expression data from The Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 
2012). Expression values were RMA normalized and the background was corrected 
with R package affy. Results are shown for the most variable probe 227458_at. 
2.15 Chromatin Immunoprecipitation (ChIP) 
LN-2683-GS cells were plated at 2.2M per 9 ml of B27 in 10 cm petri dishes. 
Three days after plating 1µM JQ1, or 0.1% DMSO as control was added to the plate 
together with 1000 Units/ml of Interferon-alpha (Peprotech). The cells were harvest-
ed 2 hours after and washed with PBS. ChIP was performed using iDeal ChIP-seq 
kit for Histones x24 from Diagenode. Briefly, cells were cross-linked by adding meth-
anol free formaldehyde (Thermo Fisher Scientific) to a final concentration of 1% in 
PBS for 8 minutes, then 125 mM Glycine was added for 5 minutes to quench the 
formaldehyde. After the cells were kept on ice and washed twice with 1ml cold PBS. 
The pellets were snap frozen and kept in -80C until further use. Then, the cell mem-
branes were lysed and nuclei extracted. The shearing was performed in 200µl iS1 
shearing buffer supplemented with protease inhibitors (Diagenode or Roche) and 
20mM Sodium Butyrate (Sigma). The chromatin was sheared on ice with 50% ampli-
tude at 10x 30 second cycles of 1 sec on /1 sec off, with 2 minute incubation on ice 
in between by Bandelin Sonoplus Sonifier with 2.5mm needle. The chromatin was 
cleared by 10 minutes centrifugation at 16,000g at 4C. 50µl of the supernatant were 
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kept for sheared chromatin analysis and the rest (150µl) was snap-frozen for further 
immunoprecipitation. 
For sheared chromatin analysis, RNA was eliminated by adding 1µl of RNAse 
(10 mg/ml, Sigma) and 3.125 µl of 5M NaCl and incubating for 1 hour at 37 C. Then 
the sample was reverse cross-linked by overnight incubation at 65 C. DNA was ex-
tracted with phenol/chloroform/isoamyl alcohol and precipitated in ethanol at -80C. 
The ethanol was removed and the dried pellets were dissolved in 15µl TE buffer. 10 
µl were used for 1.5% agarose gel analysis and 5 µl for Fragment analyzer. The 
samples with the fragment length100-600 bps were used for subsequent immuno-
precipitation. 
2.16 Stereotactic Orthotopic Xenograft Injections into the Mouse Brain 
6-8 weeks NOD scid gamma knockout (NSG (Jax name: NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ))	males born in-house were used. The injection was performed as 
described in (Vassallo et al., 2016), which was sterotactically in the striatum (coordi-
nates: bregma 0.5mm anterior, 2mm lateral and 3mm ventral). 100,000 U87MG cells 
in 5µl of HBSS with phenol red, no calcium, no magnesium (Thermo Fisher Scien-
tific) were injected with a micro pump in 1 minute. The syringe was slowly (1min) lift-
ed 5 minutes after the injection to avoid cell reflux. The end-point criteria were either 
15% weight loss, or the presence of neurological symptoms (paresis, ataxia, rota-
tion). 
(+)-JQ1 was dissolved in DMSO at 100 mg/ml and then diluted 1:10 in 10% 
(2-Hydroxypropyl)-b-cyclodextrin (Sigma). The control was DMSO dissolved 1:10 in 
10% (2-Hydroxypropyl)-b-cyclodextrin (Sigma). The mixture was sonicated at 37C 
for 5 minutes to dissolve and injected i.p. at 1% of the body weight (final concentra-
tion 100 mg/kg). 4 hours later mice were sacrificed by CO2 inhalation.  
2.17 Tissue Processing and immunohistochemistry 
The fresh mouse brain was cut using a brain mold.  The central part of the 
brain (5mm) was frozen in O.C.T. compound (Tissue-Tek) in isopentane on liquid 
nitrogen. Hematoxylin and Eosin (H&E) staining of frozen block was done to deter-
mine the location of the tumour in the mouse brain and used as a reference to 
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macrodissect the tumour from mouse brain with Cryostat. 15 mg of frozen tissue 
were used for subsequent mRNA isolation. 
The remaining tissue was fixed in 4% formalin for 4 hours, rinsed with water 
and transferred to 70% ethanol. The tissue was dehydrated through the series of 
ethanol baths in a tissue processor and embedded in paraffin. The sections were cut 
and human PD-L1 staining PD-L1 was performed with anti-PD-L1 antibody (clone 
SP263, Roche Ventana, #790-4905) was used for. H&E staining of adjacent sections 
was performed to verify the tumour location. 
2.18 Statistical analysis of experiments 
Statistical analysis of the experiments was performed using GraphPad Prism 
7 Software and with R-3.2.2 (R Core Team, 2015). Bioconductor (Gentleman et al., 
2004) packages for specific tasks are listed in the relevant sections. The Student t-
test was used to compare the variables between two groups, and 2-way ANOVA to 
compare the variables for more complex experimental design. P-values lower than 
0.05 were considered statistically significant. Significance is indicated with asterisks: 
1 asterisk (*) meaning that P < 0.05, 2 (**) when P < 0.01, 3 (***) when P < 0.001, 
and 4 (****) when P < 0.0001. Data are presented as mean values, error bars repre-
sent standard deviation unless indicated otherwise.	
 

		
 Results Chapter 3
3.1 Effects of BETi JQ1 on cell viability of GBM cell lines 
First, we assessed cell viability of a panel of adherent GBM cell lines in re-
sponse to a small-molecule inhibitor of BET proteins ((+)-JQ-1, hereafter JQ1) (Fig. 
3:1 A, B). As a result, cell viability of 4 tested GBM cell lines was reduced upon 72-
hour exposure to JQ1, and remained constant when treated with inactive enantiomer 
(-)-JQ1. U87MG showed slightly higher sensitivity to JQ1 than LN-18, LN-428 and 
BS-153. Even when GBM cells were treated with the highest concentration 30 µM 
JQ1, a proportion of cells visually appeared as viable. With this observation and the 
reports published in other cancer cell lines (Delmore et al., 2011; Tolani et al., 2014), 
we tested whether U87MG cells exhibited β-Galactosidase activity, a marker of cellu-
lar senescence (Kuilman et al., 2010) (Fig. 3:1 C, D). Indeed, we detected an in-
crease of the fraction of β-Gal positive cells exposed to (+)-JQ1 compared to inactive 
enantiomer (-)-JQ1 or DMSO. 
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Figure 3:1. JQ1 decreases cell viability of adherent GBM cell lines, and induces 
β-Galactosidase in U87MG. 
(A) Cell viability of LN-18, LN-428, BS-153, and U87MG was determined after 72-
hour incubation with 3-fold serial dilutions of (+)-JQ1 and normalized to DMSO treat-
ed control. Data represent a mean of 3 independent experiments; error bars are 
SEM.  
(B) The same as (A) for (-)-JQ1.  
(C) Representative microphotographs of Senescence-Associated β-Gal assay. 
U87MG cells were treated with 1µM (+)-JQ1, (-)-JQ1 or DMSO for 72 hours.  
(D) Quantification of Senescence associated β-Gal assay for U87MG cells. The re-
sults represent a summary of 3 independent experiments. Error bars are SD, signifi-
cance determined with unpaired one-sided t-test. 
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3.2 Effects of JQ1 treatment on glioma sphere lines 
Next, we focused of glioma sphere lines (GS-lines) that, in our opinion, repre-
sent a better model of GBM (see chapter 1.7). Of note, LN-2540-GS and LN-2669-
GS were contaminated with mycoplasma, whereas all the other cell lines were nega-
tive for mycoplasma. Cell viability of three tested GS-lines was reduced after 72-hour 
exposure to (+)-JQ1 and remained unchanged when treated with its inactive enanti-
omer (-)-JQ1 (Fig.3:2 A). There was no difference in response between the tested 
GS-lines; half maximal inhibitory concentrations (IC50) were about 15 µM for all three 
tested GS-lines. When compared to published data of cancer cell lines (IC50 from 
3nM to 6 µM) treatment (Todaro et al., 2014) or to previously obtained data with ad-
herent GBM cell lines, GS-lines seemed to be more resistant to JQ1 (Table 3:1, Fig. 
3:2 A). The observed reduced sensitivity could have been due to the fact that GS-
lines are slow-growing with population doubling times between 4-15 days (Table 
6:1), which is longer than most of the commonly used cancer cell lines.  
Table 3:1. IC50 values (concentrations of JQ1 that 
give half-maximal inhibition) of a panel of glioblasto-
ma cell lines including sphere lines. 
 
 
 
Next, we focused on more long-term effects and performed neurosphere for-
mation assay in the presence of JQ1 (serial dilution in DMSO starting from 4 µM) 
(Fig.3:2 B, D). Here we set the cells as single cell suspension and added the drugs 
on the same day before neurospheres were formed. Twenty-one days after seeding, 
we counted the number of spheres and observed that JQ1 impaired the capacity of 
gliomasphere formation of all four tested GS-lines, but to different extend. As little as 
0.25µM JQ1 was sufficient to reduce 4 times the number of spheres of LN-2207-GS, 
while for LN-2669-GS a concentration of 1µM was required. Importantly, 2µM of JQ1 
was sufficient to completely block sphere formation in 3 of 4 tested GS-lines.  
Cell line (+)-JQ1 IC50  
U87MG 1.4 µM 
LN-18 2.6 µM 
BS-153 3.3 µM 
LN-428 11.6 µM 
LN-2683-GS 18.6 µM 
LN-2540-GS 8.9 µM 
LN-2207-GS 5.8 µM 
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Then we assessed whether decreased cell viability and sphere formation were 
due to cell cycle arrest or programmed cell death. The proportion of cells in S-phase, 
as determined by the BrdU incorporation assay (Fig.3:2 E) was lower in LN-2207-GS 
cells treated with 1µM JQ1 for 5 days, whereas we did not observe difference in cell 
cycle distribution for LN-2683-GS. The effect on the reduced number of cells in S-
phase was fully reversible upon drug withdrawal after 5-days of treatment in LN-
2207-GS, indicating the absence of cell cycle G1 arrest that was previously associ-
ated with BETi treatments in cancer models (Boi et al., 2015; Delmore et al., 2011). 
Finally, we observed that 5-day treatment with 1µM JQ1 was sufficient to induce 
apoptosis in LN-2207-GS and LN-2683-GS evaluated by the presence of band of 
cleaved poly (ADP-ribose) polymerase (c-PARP). 
3.3 MYC is down regulated upon pharmacological BET inhibition 
Since MYC downregulation had been previously associated with pharmaco-
logical BET inhibition (Delmore et al., 2011), we examined the expression of MYC on 
mRNA and protein levels after 48-hour treatment of GS-lines with 1µM JQ1. As a 
result, C-MYC and N-MYC levels were reduced in all glioma models tested (Fig.3:2 
F-H). Moreover, the protein levels of C-MYC were significantly reduced upon treat-
ment with JQ1 in 3 tested GS-lines and not affected by (-)-JQ1. While MYC overex-
pression or hyper activation is believed to be one of the most common drivers of 
cancer, GBM is certainly not a MYC-driven malignancy. Indeed, MYC is not com-
monly amplified in GBM. And only 16 cases out of 129 IDH wild type GBMs ap-
peared to have copy number alterations or mRNA up regulation according to TCGA 
(http://www.cbioportal.org/, (Gao et al., 2013)). 
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Figure 3:2. Effects of JQ1 on glioma sphere lines.  
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(A) Cell viability of LN-2207-GS, LN-2540-GS, and LN-2683-GS was determined af-
ter 72 hour incubation with 3-fold serial dilutions of (+)-JQ1 and (-)-JQ1 and was 
normalized to DMSO treated control. Data represent a mean of 3 independent exper-
iments; error bars are SEM.  
(B) Quantification of neurosphere formation assay of LN-2207-GS, LN-2540-GS, LN-
2683-GS, and LN-2669-GS. The spheres with a diameter larger than 50 µm were 
counted 21 days after addition of indicated concentration of (+)-JQ1. Data represent 
the mean of 4 wells; error bars are SD. Representative of at least 3 independent ex-
periments. Reported P-values are determined by 2-way ANOVA and adjusted to ac-
count for multiple testing using statistical hypothesis Dunnett test.  
(C) Western blot for total PARP, cleaved PARP (c-PARP) and Tubulin (loading con-
trol) of lysates of LN-2683-GS and LN-2207-GS 10 days after treatment with 1µM 
(+)-JQ1 or DMSO control.  
(D) Representable image of neurosphere formation assay taken after a 21-day incu-
bation of LN-2683-GS with 0.5µM (+)-JQ1 and DMSO control.  
(E) BrdU incorporation assay of LN-2207-GS and LN-2683-GS treated with 1µM (+)-
JQ1, (-)-JQ1, and DMSO. For 5 days on/5 days off condition the medium was 
changed to DMSO containing normal medium after 5 days of treatment. Data repre-
sent summary of 3 independent experiments. *, P-value<0.05 by paired t-test.  
(F) qRT-PCR analysis of C-MYC and N-MYC gene expression after 48 hours treat-
ment with 1µM (+)-JQ1. The data represent one of at least 3 independent experi-
ments; P-values were determined by paired t-test.  
(G) Western blot analysis of C-MYC and Tubulin loading control of GS-lines treated 
with 1µM (+)-JQ1, 1µM (-)-JQ1 or DMSO for 48 hours.  
(H) Densitometry of Western blots (G). Data represent mean of 3 independent exper-
iments, error bars are SD. *, P-value<0.05, by paired t-test. 
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3.4  BET inhibition induces differentiation-like phenotype in LN-2683-GS 
Interestingly, we observed that after as short as 24-hour incubation with 1µM 
JQ1, LN-2683-GS tends to become adherent and the cells form protrusions (Fig.3:3 
A). This observation raised the question whether LN-2683-GS undergoes differentia-
tion upon pharmacological BET inhibition. First, we assessed markers of neuronal 
(TUJ1, neuronal specific class III beta-tubulin) and astrocytic (GFAP, glial fibrillary 
acidic protein) differentiation by qRT-PCR after 24-hour treatment with 1µM JQ1. 
And we observed that TUBB3 (gene coding for TUJ1) was almost 4 times up regu-
lated after 24-hour treatment with 1µM JQ1 compared to DMSO control (Fig.3:3 B). 
On the protein level elevation of TUJ1 was detected 5 and 10 days after JQ1 addi-
tion on Western Blot (Fig.3:3 C) and confirmed by Immunofluorescence 10 days after 
JQ1 addition (Fig.3:3 D). Induction of the neuronal specific beta-tubulin III indicates 
that JQ1 may stimulate a program of differentiation into neuron-like cells that was not 
reversible upon drug withdrawal after 5 days (data not shown). 
	
Figure 3:3. JQ1 induces differentiation-like phenotype in LN-2683-GS.  
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(A) Representative microphotographs of LN-2683-GS treated with JQ1 or DMSO 
control for 10 days.  
(B) qRT-PCR analysis of TUBB3 (TUJ1) and GFAP after 48 hour treatment with 1µM 
(+)-JQ1 or DMSO control. Data represent mean of 4 independent experiments, error 
bars are SD, and P-values were determined by paired t-test.  
(C) Western blot analysis of TUJ1 and loading control GAPDH of lysates of LN-2683-
GS treated with 1µM (+)-JQ1 for 2, 5, and 10 days.  
(D) Representative immunofluorescence images of LN-2683-GS spheres after 10-
day treatment with JQ1, or with DMSO stained with anti-TUJ1 antibody (green) and 
DAPI (blue). Scale bar is 100 µm.  
3.5 BET protein inhibition causes extensive changes of transcriptome  
In order to identify the pathways that are affected by pharmacological BET in-
hibition we performed differential gene expression profiling by RNA-sequencing 
(Fig.3:4 A). First, we performed principal coordinate analysis on distance matrix of 
raw read counts. The factorization of distance matrix aids at visualizing the differ-
ences between the expression profiles of different samples in two dimensions 
(Fig.3:4 B). Different replicates clustered together, while samples from different time 
points formed distinct clusters. Importantly, we obtained perfect separation between 
JQ1 treated and control on the first principal coordinate (x-axis). While the second 
principal coordinate (y-axis) was explanatory for the different time lapses that LN-
2683-GS cells were treated with JQ1. 
After that, we performed differential gene expression analysis with R package 
edgeR. We detected that over a thousand genes were significantly differently ex-
pressed between JQ1 treated and control conditions. As many as 598 genes were 
identified to be up regulated and 1278 genes were down regulated after filtering for 
genes whose expression changed 2 folds compared to the baseline (0 hours) in at 
least one time point and that pass 0.001 threshold for Bonferonni corrected P-value. 
The top 100 genes are visualized in an expression heatmap (Fig.3:4 C). It is worth 
mentioning that among the top up regulated genes there was HEXIM1, which is a 
negative regulator of the positive transcription elongation factor b (P-TEFb), the mas-
ter modulator of RNA polymerase II during transcriptional elongation (Chen et al., 
2014)	(Michels et al., 2004). Remarkably, HEXIM1 was reported to be increased af-
ter treatment with JQ1 in T cells (Banerjee et al., 2012) in lymphoma (Chapuy et al., 
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2013), and in neuroblastoma (Puissant et al., 2013), and in adherent GBM models 
(Berenguer-Daize et al., 2016). 
In order to identify gene sets that are affected by pharmacological BET inhibi-
tion we performed gene set enrichment analysis (GSEA) and reported here the top 
15 down regulated and the 15 up regulated gene sets (Fig.3:4 D,E). GSEA of JQ1-
treated and control GS cells revealed that signatures of Interferon-α response genes 
were significantly decreased in JQ1-treated cells. Moreover, in both up regulated and 
down regulated signatures, HDAC targets or gene sets of cells treated with HDACi 
Trichostatin A were detected (marked in bold in Fig.3:4 D,E). Interferon-α response 
and HDAC targets are the signatures that we decided to focus on in the current 
study.  
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Figure 3:4. Transcriptome-wide analysis of the effects of JQ1.  
(A) Experimental set-up of differential gene expression analysis by RNA-seq. LN-
2683-GS cells were treated with 1µM (+)-JQ1 or DMSO control for 4, 12, 24, and 48 
hours, experiment was repeated 3 times, and mRNA was subjected to sequencing. 
(B) Principal coordinate analysis of the raw read counts of RNA-seq data. PC1, PC2; 
principal coordinates 1 and 2. FC; fold change.  
(C) Heatmap of log2FC of top 100 differentially expressed genes (log2FC>1) based 
on Bonferroni adjusted P-value.  
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(D-E) Top 15 down regulated (D) and up regulated (E) gene sets based on gene set 
enrichment analysis with MSigDB database. q-value is Bonferroni corrected for mul-
tiple testing. Gene sets in bold were selected for subsequent analysis and validation. 
3.6 Expression of interferon stimulated genes is reduced upon JQ1 treat-
ment. 
Interferon signature in GBM was previously reported by our laboratory when 
gene expression profiles of 80 GBMs were interrogated in order to identify expres-
sion signatures (Murat et al., 2008). One of the identified expression signatures was 
cluster called G12 that consisted of ISGs. Probes were re-annotated to GRCh37 ge-
nome assembly and GBMs were assigned to four molecular subtypes (Verhaak et 
al., 2010) (Fig.3:5 A). Interestingly, the probes in G12 cluster that had not been an-
notated in 2008 currently belonged to ISGs. We did not observe enrichment of mes-
enchymal GBMs in ISG positive (right) part of the heatmap, and non-tumoural brain 
was found to have no expression of ISGs, as one would have expected. Further-
more, we validated the consistency of the cluster structure in TCGA GBM expression 
data (Fig.3:5 B). 
From HALLMARK_INTERFERON_ALPHA_RESPONSE gene set we chose 
two genes OAS1 and MX1 for validation experiments, since they are among the 
most down regulated. (Fig. 3:6 A), they belong to G12 cluster (Fig.3:5 A), and they 
appeared to be classical ISGs that had ISRE element in the promoter. In order to 
increase the translation value of the work we also included CD274 (PD-L1), which is 
a member of G12 cluster (Fig.3:5 A) in the validation experiments.  
In order to validate the reduction of ISGs upon JQ1 treatment, we boosted the 
signalling by priming GS-lines with IFN-α for 4 hours and then added JQ1 for subse-
quent 4 hours. We detected a strong reduction of ISGs OAS1, MX1 and CD274 
mRNA in JQ1 treated GS-lines compared to DMSO control (Fig.3:6 B, D). Since 
CD274 is an IFN-γ response gene	(Garcia-Diaz et al., 2017) we repeated the exper-
iment with IFN-γ and confirmed repression of induced CD274 gene upon JQ1 treat-
ment in the GS-lines. We validated the repression of IFN-induced PD-L1 upon JQ1 
treatment also on the protein level (Fig. 3:6 F,G). Importantly, BET inhibition by JQ1 
greatly diminished both IFN-α and IFN-γ-induced PD-L1 on the protein level in GS-
lines. 
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Both IFN-α and IFN-γ signal through the Janus Activated Kinase (JAK)-Signal 
Transducer and Activator of Transcription (STAT) pathway. To activate the transcrip-
tion of target genes (ISGs), pSTAT1 needs to translocate to the nucleus as homodi-
mer or heterodimer with pSTAT2. In order to exclude possible effects of JQ1 on 
JAK/STAT signalling per se we examined pSTAT1 levels in the nucleus of GS-lines 
after priming with IFN-α or IFN-γ. While total STAT1 and pSTAT1 were increased in 
the nucleus after IFN priming, we did not observe any change in JQ1 treated GS-
lines compared to DMSO control (Fig.3:7 and Fig. 6:1). 
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Figure 3:5. Interferon response gene signature in GBM. 
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(A) Heatmap of the interferon gene cluster (G12) identified in the GBM transcriptome 
(Murat et al., 2009). The expression values (Affymetrix gene probes) are log trans-
formed, centered and normalized. The GBM samples are annotated with a colour 
code according to the expression subtypes (Verhaak et al., 2010). NTB, non-
tumoural brain. CD274, a member of the G12 cluster, is marked in violet.  
(B) Plots of pair-wise RV coefficient tests between NCHaffy	 (Murat et al., 2009), 
TCGAaffy and TCGArnaseq datasets (Brennan et al., 2013). Histograms of simulat-
ed values and observed value (straight line); and bivariate scatterplots between 
semi-matrices of distances. 
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Figure 3:6. Expression of interferon-stimulated genes is reduced upon JQ1 
treatment.  
(A) Heatmap of log2FC of expression of Interferon response gene set from MSigDB 
database (HALLMARK_INTERFERON_ALPHA_RESPONSE) in LN-2683-GS treat-
ed with 1µM JQ1 for 4, 12, 24 and 48 hours.  
(B, D) qRT-PCR analysis of CD274, MX1, and OAS1 in (B) LN-2683-GS and (D) 
LN3704-GS primed with Interferon-α (1000 U/ml) for 4 hours, then with JQ1 (1µM) 
for 4 hours.  Data represent mean of 3 independent experiments. Error bars are SD. 
Reported P-values were defined by 2-way ANOVA and adjusted to account for mul-
tiple testing using statistical hypotheses Sidak test.  
(C, E) qRT-PCR analysis of CD274 in (C) LN-2683-GS, and (E) LN-3704-GS primed 
with Interferon-γ (20 ng/ml) for 4 hours, then with JQ1 (1µM) for 4 hours. Data repre-
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sent mean of 3 independent experiments. Error bars are SD. Reported P-values are 
defined by 2-way ANOVA and adjusted to account for multiple testing using statisti-
cal hypothesis Sidak test.  
(F-G) Western blot for PD-L1 and GAPDH (loading control) in (F) LN-2683-GS and 
(G) LN-3704-GS primed with Interferon-α (1000 U/ml) or Interferon-γ (20 ng/ml) for 4 
hours, and then treated with JQ1 (1µM) for 4 hours. Data is representative of 3 inde-
pendent experiments. Arrows point at specific band for PD-L1. 	
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Figure 3:7. pSTAT1 levels in the nucleus are not affected by JQ1. 
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(A) Western blot analysis of nuclear and cytosolic fractions of LN-2683-GS (A) that 
were primed with IFN-α (1000 U/ml) or IFN-γ (20ng/ml) for 4 hours, then JQ1 (1µM) 
was added for 4 hours. Histone H3 and GAPDH were used to verify separation of 
fractions.  
(B) The same as (A) for LN-3704-GS.  
(C) Densitometry of pSTAT1 versus STAT1 bands of (A-B). The data represent a 
summary of 3 independent experiments, error bars are SD. ns, P-value>0.05, by 
paired t-test. Uncropped blots can be found in Supplementary Fig. 6:1. 
3.7 GBM cell lines may endogenously express ISGs including CD274 (PD-
L1), and their expression is reduced upon JQ1 treatment. 
Bradner and others demonstrated that some ovarian cancer cell lines may 
endogenously express PD-L1 and its expression was regulated by BRD4, hence 
BETi suppressed PD-L1 expression (Zhu et al., 2016). Like in ovarian cancer cell 
lines (Zhu et al.) CD274 is expressed endogenously in some commonly used GBM 
cell lines like U87MG and LN-18 (Fig. 3:8 F). We confirmed PD-L1 expression on 
protein level in U87MG in vitro (Fig. 3:8 A) and observed membranous staining on 
the immunohistochemistry of U87MG orthotopic mouse xenografts (Fig. 3:8 E). To 
determine whether JQ1 reduced expression of endogenous MX1, OAS1, and CD274 
we treated U87MG and LN-18 cells with 1µM JQ1 for 48 hours. As a result, mRNA of 
tested ISGs was largely reduced, and PD-L1 was diminished on protein level as well 
(Fig. 3:8 B-D). 	
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Figure 3:8. GBM cell lines may endogenously express ISGs including CD274 
(PD-L1), and their expression is reduced upon JQ1 treatment. 
(A) Western blot analysis of endogenous PD-L1 levels in a panel of GS-lines, 
U87MG and ovarian cancer cell line PEO1 and OVCAR3 previously reported to have 
endogenous PD-L1 expression (Zhu et al., 2016) that were used as a positive control 
for the antibody. The arrow points the specific band for PD-L1 protein.  
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(B) Western blot analysis of PD-L1 in U87MG and LN-18 cell lines that were treated 
with 1µM JQ1 for 48 hours. GAPDH served as a loading control.  
(C-D) qRT-PCR analysis of CD274, MX1, OAS1 in (C) U87MG and (D) LN-18 cell 
lines treated with 1µM JQ1 for 48 hours. Reported P-values are determined by 2-way 
ANOVA and adjusted to account for multiple testing using statistical hypothesis Sid-
ak test.  
(E) Representative images of immunohistochemistry of PD-L1 and H&E of adjacent 
sections of U87MG xenograft in NSG mice. Scale bar is 50µm.  
(F) Relative expression of CD274 (227458_at probe) in glioma cell lines from CCLE 
(Barretina et al., 2012). Bar plots for LN-18 and U87MG are marked in blue. RMA, 
Robust Multi-Array Average. 
3.8 CD274 (PD-L1) is endogenously expressed in U87MG orthotopic xeno-
grafts and its expression is reduced upon a single injection of JQ1. 
In order to determine the effects of JQ1 on ISGs expression in vivo we utilized 
orthotopic mouse xenografts of U87MG cells (Fig. 3:9 A). This model forms a fast-
growing aggressive tumour, often hypoxic (Berenguer-Daize et al., 2016). Of note, 
excellent brain permeability by JQ1 was previously reported in healthy mice (Matzuk 
et al., 2012). Survival benefit of mice bearing orthotopic U87MG xenografts treated 
with BETi OTX015 compared to vehicle control was already shown (Berenguer-
Daize et al., 2016). We thus decided to focus on short-term treatment effects on the 
gene transcription level. For in vivo experiments the injected mice were allowed to 
develop brain tumours for 15-22 days. First, we confirmed that PD-L1 expression 
was preserved in U87MG xenografts (Fig. 3:8 E). When mice exhibited weight loss 
and/or neurological symptoms they were treated with 100 mg/kg JQ1 or vehicle 
DMSO control (i.p.). After 4 hours the brains were harvested and CD274, OAS1, 
MX1 and C-MYC expression was determined in marcodissected brain tumours. In-
deed, a significant decrease in CD274 and OAS1 expression was detected, whereas 
MX1 and C-MYC mRNAs were not affected by 4-hour JQ1 treatment (Fig. 3:9 B). 
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Figure 3:9. CD274 (PD-L1) is endogenously expressed in U87MG orthotopic 
xenografts and its expression is reduced upon a single injection of JQ1. 
(A) Schematic representation of the in vivo experiment. Nod-skid gamma knockout 
male mice were stereotaxically injected with 100,000 U87MG cells. After 15-22 days 
mice exhibited symptoms and were injected with 100 mg/kg JQ1 or DMSO vehicle 
control i.p. for 4 hours, and then sacrificed.  
(B) qRT-PCR analysis of CD274, MX1, OAS1, and C-MYC in U87MG xenografts. 
n=5 mice per group pulled from 3 independent experiments. Reported P-values were 
determined by 2-way ANOVA adjusted to account for multiple testing using FDR ap-
proach by two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli. 
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3.9 JQ1 and TSA act synergistically to reduce cell viability of GS-lines 
GSEA of JQ1 treated LN-2683-GS also revealed enrichment of several gene 
sets related to HDACi (marked in bold in Fig. 3:5 D,E). Interestingly, all the identified 
gene sets were discovered in cells treated with Trichostatin A (TSA), a small mole-
cule inhibitor of HDACi. In the literature, similarity between the effects of HDACi and 
BETi on the transcriptome level has been described from normal cells and cancer 
models (Bernasconi et al., 2016; Bhadury et al., 2014; Vazquez et al., 2017). Given 
the resemblance, we decided to test whether the combination of JQ1 with the HDACi 
TSA would be synergistic in GS-lines. For this we treated LN-2683-GS and LN-3708-
GS with 64 possible combinations of JQ1 and TSA from 0µM to 10µM for a 3-day 
assay and from 0µM to 2µM for a 10-day assay (Fig. 3:10 A-D). We performed anal-
ysis of dose-response matrix (Fig. 3:10 B) and determined the range of concentra-
tions where synergistic drug interactions occur (red part of JQ1-TSA interaction 
landscape (Fig. 3:10 C)). Importantly, the shape of drug interaction landscapes re-
mained the same for 3 biological experiments (data not shown) that confirmed the 
validity of chosen synergy analysis methodology. Based on the performed analysis, 
5% of LN-2683-GS cells after 3 days and 9% after 10 days die due to the synergistic 
drug interactions (for LN-3708-GS 15% after 3 days, and 4% after 10 days). Next 
step would be to test this drug combination in mouse xenografts. 
3.10 JQ1 and TSA produce synergistic effects to repress transcription of IFN-
induced, but not endogenously expressed, ISGs 
In order to test whether TSA produces effects on transcription level of ISGs 
similar to the ones observed with JQ1, GS-lines primed with IFN-α were treated with 
1µM JQ1, 1µM TSA or the combination of 0.5µM JQ1 and 0.5µM TSA (Fig. 3:10 F). 
Indeed, TSA reduced the expression of MX1, OAS1, and CD274 to the same extend 
as JQ1, apart from CD274 in LN-3704-GS, which was significantly higher in TSA 
treated cells. Moreover, the combination of TSA and JQ1 reduced the expression of 
ISGs more than JQ1 alone in both GS-lines, indicating synergistic effects of the ther-
apy on gene transcription level as well as on cell viability.  
Given the effects of the combination of TSA and JQ1 on IFN-induced ISGs, 
we tested whether TSA is potent to reduce the expression of innate ISGs in adherent 
GBM cell lines as well. Surprisingly, we marked a completely different effect (Fig. 
Results	
	 65	
3:10 G, H). In fact, TSA was not reducing the expression of innate ISGs, even slight-
ly induced expression of CD274 in LN-18. In addition, TSA did not affect endoge-
nous PD-L1 expression on the protein level either (Fig. 3:10 I,K). Hence, there are 
fundamental differences in modulation ISGs expression by JQ1 in GS-lines and 
GBM cell lines will be discussed in the next chapter.  
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Figure 3:10. Combination of JQ1 with TSA shows synergy in reduction of cell 
viability and repression of Interferon stimulated genes in GS-lines. 
(A-D) Combination assay in LN-2683-GS treated with serial 2-fold dilutions of JQ1 
and TSA starting with 2µM for 10 days. Representative of 3 independent experi-
ments.  
(A, D) Single drug cell viability curves for LN-2683-GS treated with (A) TSA and (D) 
JQ1. Data represent mean of 3 plates (technical replicates).  
(B) Combination matrix of cell inhibition. 100% is inhibition of LN-2683-GS cells 
treated with lethal 1µg/ml Actinomycin D, 0% is inhibition of LN-2683-GS exposed to 
DMSO control. Data represent mean of 3 wells (technical replicates).  
(C) Combination landscape showing the synergistic range of concentrations of TSA 
and JQ1 in red, and additive in green.  
(E-F) qRT-PCR analysis of CD274, MX1, and OAS1 in (E) LN-2683-GS and (F) LN-
3704-GS primed with Interferon-α (1000 U/ml) for 4 hours and then treated with 1µM 
JQ1, 1µM TSA or the combination of 0.5µM JQ1 and 0.5µM TSA for 4 hours. Data 
represent mean of 3 independent experiments, error bars are SD. Reported P-values 
were determined by 2-way ANOVA and are adjusted to account for multiple testing 
using statistical hypothesis Sidak test. 
(G-H) qRT-PCR analysis of CD274, MX1, and OAS1 in (G) U87MG and (H) LN-18 
treated with 1µM JQ1, 1µM TSA or the combination of 0.5µM JQ1 and 0.5µM TSA 
for 48 hours. Reported P-values were determined by 2-way ANOVA and adjusted to 
account for multiple testing using statistical hypothesis Sidak test. 
(I) Western blot analysis of PD-L1 and Vinculin loading control of U87MG and LN-18 
treated with 1µM JQ1, 1µM TSA or the combination of 0.5µM JQ1 and 0.5µM TSA 
for 48 hours.  
(J) Densitometry of (I). Data represent mean of 3 independent experiments. Error 
bars are SD. Reported P-values were determined by 2-way ANOVA and adjusted to 
account for multiple testing using statistical hypothesis Sidak test. 
 

		
 Discussion  Chapter 4
4.1 JQ1 treatment seems to induce senescence-like phenotype in adherent 
GBM cell lines 
BET inhibitors such as JQ1 have demonstrated efficacy in various cancer 
models, and clinical analogues of JQ1 have been tested in several malignancies ac-
cording to the rapidly expanding literature (reviewed in (Stathis and Bertoni, 2017)). 
In this study, we evaluated the potential efficacy of JQ1 in glioblastoma (GBM) mod-
els. At first, we observed a reduction of cell viability of regular GBM cell lines (Fig.3:1 
A). Moreover, GBM cell lines exhibited markers of senescence, reduction of cells in 
S-phase (data not shown) and presence of SA-β-Gal activity (Fig.3:1 C, D). In fact, 
the induction of SA-β-Gal with incomplete growth arrest in response to BETi was al-
ready reported in cancer models in vitro (Boi et al., 2015; Delmore et al., 2011). 
4.2 Long exposure to JQ1 blocks the ability of GS-lines to form secondary 
gliomaspheres  
Next, we focused on glioma sphere lines (GS-lines), and observed that cell 
viability of GS-lines was reduced upon JQ1 exposure. However, compared to pub-
lished reports and the results obtained with adherent cell lines previously, the tested 
GS-lines would fall into the resistant category, since even the highest concentration 
tested (30µM) was not lethal (Fig.3:2 A) (Todaro et al., 2014). This resistance might 
have been linked to the slow-cycling nature of GS-lines (population doubling times 
from 4 to 15 days, Table 6:1) and a neurobasal growth medium without serum that 
we use specifically to culture GS-lines.  
Then, we confirmed the results of Cheng and colleagues (Cheng et al., 2013) 
that JQ1 compromised the ability of glioma spheres to form secondary glio-
maspheres. This observation is important, since it is commonly believed that retrac-
tion of GBM to cancer therapies is due to a small population of cells with stem cell 
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like features (Bao et al., 2006). Notably, 2µM JQ1 was sufficient to completely block 
the sphere formation capacity of GS-lines, and this concentration of BETi OTX015 
was therapeutically achievable in patients’ plasma. However, OTX015 did not show 
to be efficient in recurrent GBM patients (Hottinger et al., 2016).  
4.3 JQ1 seems to drive GS-lines to apoptosis  
Moreover, JQ1 did not increase the population of cells arrested in G1 of GS-
lines, as it was demonstrated in other cancer models (Boi et al., 2015; Delmore et 
al., 2011; Pastori et al., 2014). In fact, we only observed a decrease of cells in S-
phase in LN-2207-GS, which was reversible upon drug withdrawal. However, GS-
lines seemed to die apoptotically after prolonged exposure of 5 or 10 days to JQ1 
(presence of Annexin V, not shown; and cleaved PARP (Fig 3:2 C). 
4.4 MYC is down regulated upon JQ1 exposure in GS-lines 
Importantly, MYC was reported to play a central role in the rational of using 
BET inhibitors in cancer in virtually all cancer related studies published (Boi et al., 
2015; Delmore et al., 2011; Mertz et al., 2011; Ott et al., 2012). BET inhibition was 
postulated to be a therapeutic strategy to target MYC, which in its turn mediated 
transcriptional changes and repressed cell cycle progression (Delmore et al., 2011). 
In GBM models contradictory results were published concerning MYC. Pastori and 
colleagues reported that I-BET (a clinical analogue of JQ1) did not alter MYC ex-
pression in U87MG in vitro (Pastori et al., 2014). Whereas, Cheng and colleagues 
showed down regulation of MYC on both mRNA and protein levels after treatment of 
GS-lines and in their adherent pairs with JQ1 in vitro (Cheng et al., 2013). According 
to our results, MYC is down regulated after JQ1 treatment in all tested GBM models 
in vitro. Of note, our GS-line with the lowest intrinsic level of C-MYC protein LN-
2683-GS did not appear to be more sensitive to JQ1. 
4.5 LN-2683-GS seems to exhibit neuronal differentiation-like phenotype 
Furthermore, we discovered a differentiation-like phenotype of LN-2683-GS 
after exposure to JQ1, with an increased expression of neuronal differentiation 
marker neuronal specific class III beta-tubulin (TUJ1). To our knowledge, the obser-
vation that GS-lines may differentiate after treatment with JQ1 was not reported be-
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fore in GBM models. Nevertheless, there are studies that showed differentiation 
phenotype in response to JQ1 of embryonic stem cells (Gonzales-Cope et al., 2016), 
neuroblastoma cell lines (Lee et al., 2015), and paediatric glioma cells (Piunti et al., 
2017). JQ1 was also shown to inhibit differentiation of bone cells in the context of 
bone tumour osteosarcoma (Lamoureux et al., 2014), and T helper 17 cells (Cheung 
et al., 2017). In our results, a differentiation-like phenotype was only present in LN-
2683-GS, and not in six other tested GS-lines. Hence, the differentiation phenotype 
in response to JQ1 was not prevalent in GS-lines. 
4.6 Transcriptome-wide differential gene expression analysis revealed gene 
signatures affected by BET inhibition 
In our study, over a thousand of genes were differentially expressed in JQ1 
treated LN-2683-GS compared to DMSO control. This result was initially puzzling, 
since it had been shown that BETi affected a few hundreds of genes, most of which 
being associated with super-enhancers (Dawson et al., 2012; Loven et al., 2013). 
For instance, 88 genes were significantly down and 25 up regulated in multiple mye-
loma cell lines after JQ1 treatment (Delmore et al., 2011). Generally, drugs targeting 
chromatin regulators (such as HDAC, HAT or BET inhibitors) are thought to be un-
specific due to the lack of specificity of the regulators themselves. So, it could be 
possible that BET proteins are not enriched at super-enhancers in GS-lines to the 
extent reported in other malignancies, where 33% of BRD4 is bound to 1.6% of 
genes in lymphoma (Chapuy et al., 2013). 
Despite the observed major changes of the transcriptome, GSEA with MSigDB 
database helped us to make sense of the achieved RNA-seq data and resulted in 
two major discoveries:  JQ1 represses the IFN response genes; and JQ1 produces 
similar effects as an HDACi in published data sets (Fig. 3:4). Whereas, the resem-
blance with HDACi could have been predicted by the mode of action and published 
reports (Bhadury et al., 2014; Mazur et al., 2015), the relevance of ISGs repression 
to GBM was difficult to decipher.  
4.7 Epigenetic modulation of interferon response genes in cancer 
First, it is unclear why we were able to detect ISGs in cell culture, where there 
should not be any IFN present. Major producers of IFN-α are believed to be macro-
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phages, and IFN-γ is produced by T-cells in cancer microenvironment. In fact, can-
cer cells were shown to be able to produce type I IFNs themselves along with infil-
trating immune cells in the tumour microenvironment (reviewed in (Parker et al., 
2016)). Whereas, the expression of IFN-γ is only attributed to T cells and NK cells 
(Schroder et al., 2004). Moreover, if the ISGs expression was due to the presence of 
immune cells in the GBM microenvironment, the GBMs that express ISGs would 
have been of mesenchymal subtype, which is not the case based on the results from 
G12 cluster (Fig. 3:5). So, there might be a genetic or epigenetic innate mechanism 
of ISGs transcription by GBM cells. 
Indeed, our experiments demonstrated that the expression of IFN-induced or en-
dogenously expressed ISGs was repressed upon pharmacological BET inhibition; 
hence the transcription of ISGs was epigenetically regulated in in vitro GBM models. 
We discovered that expression of both endogenous or IFN-induced CD274 (PD-L1) 
is reduced upon BETi treatment in line with the results recently reported in ovarian 
cancer human cell lines (Zhu et al., 2016), and in a large panel of breast, lymphoma, 
colon adenoma murine and human cancer cell lines (Hogg et al., 2017). Both studies 
demonstrated that BRD4 is a critical mediator of CD274 expression, and regardless 
of the transcription factors present in CD274 locus, BETi were shown to block tran-
scription elongation of CD274 gene. Importantly, this effect was MYC independent, 
which is somehow in controversy to earlier published report (Casey et al., 2016).  
PD-1 inhibiting antibodies are currently being tested in the clinic for the treatment 
of glioblastoma (for example clinical trials NCT03430791, NCT02617589). Our re-
sults raise the possibility of targeting PD-L1 using small molecule BET inhibitors. It 
could be an interesting strategy for brain tumours since small molecules should bet-
ter penetrate BBB than antibodies. However, our results alone cannot tell whether 
BETi facilitate a positive immune response to kill the tumor. In order to answer this 
question one must study effects of BETi on immune cells in glioma microenviron-
ment (more details in perspectives section). Moreover, major limitation of BETi ap-
proach to PD-L1 blockade would be all other genes that are affected by BETi (Figure 
4:1). 
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There is some reported evidence of epigenetic regulation of ISGs in cancer. For 
instance, CD274 promoter is commonly silenced by methylation in IDHmt glioma, but 
not in IDHwt glioblastoma (Berghoff et al., 2015; Berghoff et al., 2017). Works pio-
neered by Stephen Baylin demonstrated that reversing aberrant methylation to nor-
mal pattern helps the tumour to reactivate its immune attraction systems 
(Chiappinelli et al., 2015). Mechanistically, they demonstrated that after exposure to 
DNMTi (5-Aza), cancer cell started to express RNA from endogenous retroviruses, 
which lead to an increased IFN signaling and viral defense gene expression, like the 
cancer cell had been exposed to a virus. In a follow-up work they showed that addi-
tion of HDACi to 5-Aza further augmented the induction of ISGs in NSCLC models 
(Topper et al., 2017). These finding are supported by the data from the clinic where 
NSCLC patients who were treated with 5-Aza (Vidaza) and HDACi Entinostat re-
sponded to immunotherapy better, that those who were treated with immunotherapy 
alone (Wrangle et al., 2013). 
4.8 Synergy between BETi and HDACi 
In our experiments combination of JQ1 and TSA showed synergism in reducing 
cell viability of GS-lines. Moreover, combination of TSA and JQ1 was also reducing 
the expression of ISGs, including PD-L1 in GS-lines. In fact, synergy between 
HDACi and BETi was previously reported in several cancers (Bhadury et al., 2014; 
Boi et al., 2015; Fiskus et al., 2014; Mazur et al., 2015; Shahbazi et al., 2016). The 
results obtained in vitro have to be validated in mouse xenografts of GS-lines, which 
will be discussed in perspectives. 
4.9 The observed difference between GS-lines and adherent GBM cell lines 
Intriguingly, the obtained results with GS-lines and adherent GBM cell lines con-
cerning modulation of ISGs were profoundly different. We demonstrated that expres-
sion of endogenous ISGs in U87MG and LN-18 was not repressed by HDACi (even 
slightly, but significantly induced in LN-18). In fact, HDACi was shown to induce 
CD274 expression in melanoma cell lines in vitro (Woods et al., 2015). Moreover, the 
combination of 5-Aza and HDACi was reported to increase ISGs expression in 
NSCLC and ovarian cancer models (Stone et al., 2017; Topper et al., 2017). Hence, 
adherent GBM cell lines gave results similar to the ones reported with 2D models of 
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other cancers in respect to response to HDACi treatment. Mario Suva mapped 
H3K27ac (mark of active genes and enhancers) in 3 GS-lines and their adherent 
pairs. Even though most of H3K27ac peaks were shared between a given GS-line 
and its adherent pair, a big part of H3K27ac peaks were specific only to a GS-line or 
only to its adherent pair. In fact, unsupervised clustering showed higher similarity 
between different GS-lines, rather than between the GS-line and its adherent pair 
(Suva et al., 2014). This suggests that the chromatin landscape, in regards to at 
least the H3K27ac mark, correlates better with the phenotypic state and probably 
culture conditions, rather than with tumour-specific characteristics. Hence, when one 
modulates the H3K27ac mark, with for example HDACi, the effects might be pro-
foundly different, which is what we have observed in our experiments. In any case, 
mechanistic details of the effect have yet to be investigated, but our data demon-
strated that the modulation of ISGs by HDACi is not a universal effect and is likely to 
be cell context-dependent. 
4.10 Experiments with orthotopic mouse xenografts 
First of all, excellent blood brain barrier permeability of JQ1 had already been 
reported in healthy mice (Matzuk et al., 2012). We first confirmed PD-L1 expression 
in U87MG xenografts by immunohistochemistry. Despite the presence of a staining 
background in mouse brain, which was probably due to the use of an anti-mouse 
and anti-rabbit cocktail of secondary antibodies (Ventana kit, Roche), U87MG xeno-
grafts exhibited a cytoplasmic staining of PD-L1.  
In order to investigate modulation ISGs in response to JQ1, we chose to treat 
the mice bearing orthotopic xenografts with JQ1 for 4 hours, since this time was 
more than enough to induce massive changes on the transcriptome of GS-lines 
(RNA-seq data) and to reduce expression of ISGs in culture. Our results demon-
strated that OAS1 and CD274 were down regulated, whereas MX1 remained un-
changed. It could have been due to the time point, since the drug needs to reach the 
brain first, and the genes modulation of which we detected were probably direct and 
early response genes. Expression of C-MYC was not affected either, but it was ex-
pected since even in culture it takes 48 hours to have significant changes in U87MG 
cells (data not shown). 
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4.11 Limitation of the current study 
A big part of the current study was based on data we have achieved from 
RNA-seq that we performed in one GS-line. However, all the subsequent experi-
ments were performed in at least 2 GS-lines, which is important to validate the re-
sults. Moreover, in vivo experiments were performed only in one model of GBM 
U87MG xenografts. This model does not recapitulate the important characteristics of 
glioblastoma, such as invasiveness. Furthermore, the origin of U87MG line is debat-
ed, however it was confirmed to be glioblastoma-derived (Allen et al., 2016). LN-
2669-GS and LN-2540-GS were contaminated with mycoplasma. Mycoplasma was 
shown to affect the biology of cell lines, for example causing significant changes in 
gene expression (Olarerin-George and Hogenesch, 2015), metabolism and many 
other aspects of cell biology (Shannon et al., 2016; Young et al., 2010). GS-line LN-
2207-GS is not tumourigenic in mice and therefore is a not a good model of the glio-
blastoma (Table 6:1). Furthermore, mice were immunocompromised, which does not 
allow recapitulating glioblastoma microenvironment. The reason we do not use 
mouse immunocompetent models of glioblastoma is that the murine tumour does not 
recapitulate the one of human origin; mutation burden of mouse glioma is low 
(Pyonteck et al., 2013; Uhrbom et al., 2002). Lastly, a major limitation of the current 
study is that all the experiments were conducted with a tool drug that has a short 
half-life and needs to be diluted in DMSO to be administered in the animals, and im-
possible to use for humans. Hence, there are a dozen of various BETi that are cur-
rently being tested in preclinical and clinical studies, most of which have limited 
blood brain barrier penetration in mice (example for I-BET (Pastori et al., 2014)). 
4.12 Perspectives 
4.12.1 Confirmation of the key results with clinically relevant BETi 
We are currently testing a clinically relevant BETi ODM-207 in our GBM mod-
els in collaboration with a pharmaceutical company Orion Pharma (Bjorkman et al., 
2016a; Bjorkman et al., 2016b). ODM-207 is now being tested in solid cancers (clini-
cal trial identifier: NCT03035591). The results could not be included in this thesis due 
to the non-disclosure agreement.  
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4.12.2 Investigation of the mechanism of ISGs repression upon pharmacological 
BET inhibition 
	
Figure 4:2. BETi suppress the expres-
sion of Interferon Stimulated genes. 
Adapted from (Zhu et al., 2016). Ac, acetyl 
group; ISGs, interferon-stimulated genes; 
Pol II, polymerase 2. 
 
 
 
 
 
 
 
Our results consistently demonstrate that JQ1 represses the expression of 
both endogenously expressed and IFN-induced ISGs in GBM models. Since, we ob-
served a strong reduction in expression after as short as 4 hours, we think ISGs are 
direct response genes of BETi. It is supported by the literature at least concerning 
CD274 gene, since BRD4 was shown to be required for tethering acetylated chroma-
tin to RNA Pol2 and therefore directly promoting transcriptional elongation of CD274 
(Hogg et al., 2017). We hypothesize that the reported mechanism concerning tran-
scriptional repression of CD274 by BETi may possibly be extrapolated to the signa-
ture of ISGs (Fig. 4:1). 
In order to test this hypothesis we are planning to perform ChIP in JQ1 and 
control conditions of IFN-primed GS-lines to assess Pol2 presence in TSSs of 
CD274, MX1, and OAS1. First, the read-out will be performed by qPCR, and if Pol2 
is detected to be absent from TSS of tested ISGs, the chipped gDNA will be se-
quenced. It might be important to include the H3K27ac mark to define active en-
hancers/super-enhancers, as well as BRD4 in order to have a better mechanistic 
insight on the transcription of ISGs. Our preliminary experiments showed that Pol2 
was present on TSS of CD274 2 hours after the induction (preliminary results, data 
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not shown). We encountered multiple technical difficulties when trying to perform 
ChIP of GS-lines, due to the absence of the standard procedure for GS-lines and 
limitation in cell number. 
4.12.3 Validation of BETi and HDACi combination  
Currently, we are working on characterizing LN-3708-GS xenografts in vivo in 
order to use this model for a preclinical trial of BETi. If BETi shows survival benefit of 
mice bearing orthotopic xenografts, we will proceed to test the combination of BETi 
and HDACi. In a second step, we are planning to validate the results obtained in 
vitro, but this time we will use clinically relevant analogues (such as ODM-207 and 
HDACi Vorinostat). The efficiency of the combination should be compared to stand-
ard of care, so one arm of tested animals should be treated with Temozolomide. 
4.12.4 Effects of BETi on the GBM microenvironment 
It would have been interesting to investigate whether BETi provokes changes 
in the immune compartment of the glioblastoma microenvironment. In fact, in the 
above-mentioned studies by S. Baylin, ISGs re-expression by 5-Aza treatment tar-
geted massive changes in immune compartment of tumour microenvironment (more 
CD45+ overall, more active CD8+Tcells, and NK cells) (Stone et al., 2017). In order 
to investigate the effects of BETi on glioblastoma microenvironment together with the 
effects on the cancer cells themselves, one must work with immunocompetent ani-
mals, or co-culture GBM cells with immune cells such as macrophages that were 
shown to be abundant in the GBM microenvironment (Bowman et al., 2016). Howev-
er, it might be not technically challenging, since immune cells might be dying in FBS 
free medium. To our knowledge, little is published on how BETi influences tumour 
microenvironment, except for one study that showed that BETi enhanced T cell per-
sistence (Kagoya et al., 2016). 
4.12.5 Future of epigenetic drugs as cancer therapies 
It is clear that the epigenome of cancer cell is altered. Even cancers with low 
mutational burden, such as paediatric cancers or IDHmt gliomas exhibit drastic 
changes of the epigenome (Biegel et al., 2014; Flavahan et al., 2016; Mack et al., 
2014). And several epigenetic drugs such as Decitabine, Azacitidine, Vorinostat 
showed a survival benefit and low toxicities in the clinics, and are currently FDA ap-
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proved (reviewed in(Jones et al., 2016)). Despite significant successes, a lot of chal-
lenges remain, such as absence of response biomarkers, and unclear mechanisms 
of response. Epigenetic drugs of the class “broad reprogrammers” (BETi, HDACi, 
HATi, DNMTi) are not specific to cancer cells; in fact normal cells cannot exist with-
out the functioning epigenome. So, clinical activity of drugs targeting “broad repro-
grammers” might always be limited by their toxicities. 
There is another type of more specific epigenetic drugs, such as inhibitors of 
mutant EZH2 or mutant IDH inhibitors. These drugs are designed to specifically tar-
get cancer cells with particular mutations; hence their toxicities should be limited. 
Finally, it was shown multiple times that the flexibility of the epigenome is 
used by cancer cells to rapidly acquire resistance to anti-cancer agents (for example 
(Brown et al., 2014; Liau et al., 2017)). Therefore, epigenetic therapies would be 
more effective when used in combination with kinase inhibitors, conventional chemo-
therapy, or immunotherapy. 
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 Supplement Chapter 6
Table 6:1. Molecular characterization and tumourogenecity of GS-lines used in the 
study. 
GS-lines LN-2207-GS LN-2540-GS LN-2669-GS LN-2683-GS LN-3704-GS LN-3708-GS 
TP53 wt p.Arg248Trp 
homozygous 
wt p.Glu224Lys/ 
p.Pro250Leu 
both 
heterozygou
s 
nd nd 
PTEN p.Tyr27Cys5
6  homozy-
gous  
c.253+5G>A 
and heterozy-
gous del of 
exons 1 to 9 
p.Asp323Valfs
X19 homozy-
gous  
*heterozygou
s del of ex-
ons 1 to 9 
nd nd 
P16/ARF homozygous 
del 
hemizygous 
del 
homozygous 
del 
homozygous 
del 
nd nd 
Tumour-
igenicity in 
nude/NSG 
mice 
Non tumour-
igenic, ic, sc 
Intra cerebral  
(Sciuscio et 
al., 2011)  sc, 
nd 
Intra cerebral  
(Sciuscio et 
al., 2011) sc, 
nd 
Intra cerebral  
(Sciuscio et 
al., 2011)  
sc, nd 
Intra cere-
bral(primary 
cells, un-
published) 
sc, nd 
Intra cere-
bral(primary 
cells, un-
published) 
sc, nd 
population 
doubling 
time 
5 days 6 days 15 days 8 days 5 days 4 days 
* sequencing data not usable; ic, intra cerebral; sc, sub-cutaneous; nd, not defined. 
LN-2683-GS was derived from recurrent glioblastoma treated by te-
mozolomide/radiotherapy in the first line (Sciuscio et al., 2011). Population doubling 
times were estimated by counting cell number 3-4 times in 2 weeks and calculating 
according to  
𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 = 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 ∗ ln (2)ln FinalConcentration − ln(InitialConcentration)	
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Table 6:2. List of primers used for qPCR. 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
GAPDH AGGTGAAGGTCGGAGTCAACG CGTTCTCAGCCTTGACGGTG 
hGAPDH CATGAGAAGTATGACAACAGCCT AGTCCTTCCACGATACCAAAGT 
C1orf43 TACGGGAGCCTGGACTTGAA AGTGTTTCGCAGATCCAGCA 
C-MYC CGACTCTGAGGAGGAACAAGAA GGATAGTCCTTCCGAGTGGA 
hC-MYC TGCTCCATGAGGAGACACC CCTCATCTTCTTGTTCCTCCA 
N-MYC TGAGCGATTCAGATGATGAAGA GCATCGTTTGAGGATCAGC 
MX1 GAAAGAGGCGAAGCGAGAG CCGTGACACTGGGATTCCT 
OAS1 GGTGGAGTTCGATGTGCTG AGGTTTATAGCCGCCAGTCA 
TUBB3 GCGAGATGTACGAAGACGAC TTTAGACACTGCTGGCTTCG 
CD274 CCATACAGCTGAATTGGTCATC CAGAATTACCAAGTGATCCTTTCA 
 
Table 6:3. List of primers used for ChIP-qPCR. 
GAPDH 
TSS 
*sequence unknown, provided by Di-
agenode 
 Myglobin 
exon2 
*sequence unknown, provided by Di-
agenode 
 CD274 TSS AAGCCATATGGGTCTGCTC TTATCAGAAAGGCGTCCCCC 
MX1 TSS ATACGTGCAGGCTTGGATGAC AGGCCCGTCTGAGGATCAA 
OAS1 TSS ACGTGTTTCCGCATGCAAAT GGCCTGGACTCACCTTTACC 
CD274 TSS 
A CTCGCTGGGCACTTTAGGAC TACTGCCCCCTAGACCATCG 
CD274 TSS 
B TTATCAGAAAGGGGGACGCC CCAACATCTGAACGCACCTTG 
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Figure 6:1. Original uncropped Western Blots for Figure 3:7. 
 
